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1 Introduction 1
1 Introduction 
 
The most important characteristic common to all higher organisms is the capability to 
coordinate the functions of different cells types. This is accomplished by a complex 
signaling network processing incoming and outgoing signals, between different cells or 
different compartments within a cell.  
A central role plays the binding of ligands to their respective receptors and the subsequent 
intracellular transmission of this signal leading to different biochemical processes like 
proliferation, differentiation, migration, adhesion or the programmed cell death, so-called 
apoptosis. Without the exact balance of the various signaling networks neither the 
development nor the survival of a higher organism would be possible. As more and more 
signaling components and pathways are discovered nowadays, it becomes apparent that 
signaling cascades are not separated linearly. On the contrary, they are highly 
interconnected and form complex networks (Downward, 2001). Thus, the regulation of 
these signaling networks is susceptible to disturbance and deregulated signal transmission 
can cause various diseases such as cancer, diabetes, immune deficiencies or cardiovascular 
diseases as well as many other (Hanahan and Weinberg, 2000; Schlessinger, 2000; 
Shawver et al., 2002). 
The Human Genome Project has identified approximately 20% of the human genome to 
encode proteins of signaling pathways, including transmembrane proteins, guanine-
nucleotide binding proteins (G proteins), kinases, phosphatases and proteases. The 
identification of 518 putative protein kinase genes and 130 protein phosphatases (Blume-
Jensen and Hunter, 2001; Shawver et al., 2002) gives rise to the assumption that reversible 
protein phosphorylation is the central regulatory element of most cellular functions 
(Cohen, 2002a). Phosphorylation and dephosphorylation by the combined action of a 
protein kinase and a protein phosphatase can alter the activity as well as the stability of a 
protein, target it for degradation, influence its subcellular localization or change a protein’s 
affinity towards interaction partners. According to their localization and their substrate 
specificity, both protein kinases and phosphatases can be subdivided into cellular and 
transmembrane molecules and into tyrosine or serine/threonine-specific kinases and 
phosphatases. The flexibility and reversibility of protein phosphorylation in combination 
with the availability of ATP as a phosphoryl donor can explain the preference of 
eukaryotic cells for this mechanism as the most common regulatory element.  
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Two important families of membrane-bound receptors are the G-protein coupled receptors 
(GPCRs) and the Receptor tyrosine kinases (RTKs). Up to date, GPCRs represent the 
largest family of signaling molecules known. They are integral membrane proteins without 
internal enzymatic activity. After ligand binding they couple to heterotrimeric G proteins 
(Coughlin, 1994; Gutkind, 1998) which are dynamically phosphorylated and thus regulate 
the levels of intracellular second messengers. RTKs have an intrinsic tyrosine kinase 
activity and are reversibly phosphorylated upon ligand binding which leads to the 
recruitment of docking and other signaling proteins (van der Geer et al., 1994).  
Examples of counterparts of these receptors are protein tyrosine phosphatases (PTPs) for 
the RTKs and G protein coupled receptor kinases (GPKs) for the GPCRs. They control the 
activity of these receptors by dephosphorylation and thereby act as regulatory components 
in order to terminate a signal after prolonged or repeated exposure to the ligand. Another 
way to control the activity of membrane-bound receptors is the internalization of receptors 
followed by their degradations or the recycling of receptors.  
Because numerous human diseases are connected to altered GPCR and RTK signaling 
pathways, numerous efforts have been taken to elucidate their signaling pathways in order 
to develop suitable drugs for their treatment. 
 
1.1 Protein tyrosine kinases 
 
Protein tyrosine kinases are important regulators of intracellular signal transduction 
pathways mediating aspects of multicellular communication and development (Cohen, 
2002b) acting by catalyzing the transfer of the γ-phosphate of ATP to hydroxyl groups of 
tyrosines on target proteins (Hunter, 1998). Tyrosine kinases play a critical role in the 
control of many fundamental cellular processes including the cell cycle, migration, 
metabolism and survival as well as proliferation and differentiation. Among the 518 
putative kinase genes 90 tyrosine kinase genes have been identified. 58 genes encode 
transmembrane receptor tyrosine kinases (RTKs) distributed into 20 subfamilies classified 
according to their structural characteristics and 32 encode cytoplasmic non-receptor 
tyrosine kinases (NRTKs) divided into ten subfamilies. 
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1.1.1 Receptor tyrosine kinases (RTKs) 
 
RTKs are type I transmembrane proteins containing an intrinsic tyrosine kinase activity. 
They are composed of a glycosylated extracellular ligand-binding domain, a single 
transmembrane domain and a cytoplasmic domain (Hubbard and Till, 2000). The 
cytoplasmic domain contains a highly conserved protein tyrosine kinase core and 
additional regulatory sequences that are subjected to autophosphorylation and 
phosphorylation by heterologous protein kinases. The structural diversity of RTK is due to 
the presence of one or several copies of immunoglobulin-like domains, fibronectin  
type III-like domains, EGF (epidermal growth factor)-like domains, cysteine-rich domains 
or other domains within the extracellular domains (Figure 1). 
 
 
Fig. 1. Subfamilies of receptor tyrosine kinases. Abbreviations: AB, acidic box; CadhD, cadherin-like 
domain; CRD, cysteine-rich domain; DiscD, discoidin-like domain; EGFD, epidermal growth factor-like 
domain; FNIII, fibronectin type III-like domain; IgD, immunoglobulin-like domain; KrinD, kringle-like 
domain; LRD, leucine-rich domain. The symbols α and β denote distinct RTK subunits (Blume-Jensen and 
Hunter, 2001).  
 
Activation of RTKs occurs via ligand-induced dimerisation followed by 
transphosphorylation of selected tyrosine residues within the cytoplasmic domain thereby 
generating docking sites for intracellular signal transducers with phosphotyrosine 
interaction domains. 
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1.1.2 EGFR family 
 
The epidermal growth factor receptor (EGFR) family consists of four RTKs: EGFR, 
HER2/neu for which no ligand has been described so far (Goldman et al., 1990), HER3 
being kinase-inactive and HER4 (Ullrich and Schlessinger, 1990).  
The EGFR is the most prominent RTK and is the first cell surface signaling protein and 
protooncogene product to be characterized by molecular genetic methods and exhibits 
prototypical features of RTKs (Downward et al., 1984; Ullrich et al., 1984). Due to its 
functional role as a proto-oncogene in viruses, the pathophysiological effects of EGFR 
mutants and its overexpression in several types of cancer, the EGFR is implicated in cancer 
development. Examples of EGFR related cancer forms are colon (Damstrup et al., 1999), 
lung and prostate (Seth et al., 1999) as well as epithelial cancer (Dong et al., 1999).  
HER2 is the preferred dimerisation partner for the EGFR, HER3 and HER4 and shows a 
high transforming activity (Beerli et al., 1995; Graus-Porta et al., 1997). The HER2 gene 
amplification for example has been linked to breast cancer (Slamon et al., 1989). 
 
1.1.3 EGF-like ligand induced activation of RTKs 
 
Activation of the EGFR family of RTKs is generally controlled by spatial and temporal 
expression of their ligands (Peles and Yarden, 1993). So far eight ligands have been shown 
to directly activate the EGFR: EGF, transforming growth factor alpha (TGFα), heparin-
binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin (BC), 
epiregulin (Epi) (Riese and Stern, 1998), cripto (Salomon et al., 1999) and epigen 
(Strachan et al., 2001). Various neuregulin (NRG) isoforms act as ligands for HER3 and 
HER4. 
Despite having distinct receptor binding specificity, all ligands share a common motif of 
30-50 amino acids in the active peptide, the so-called EGF structural unit which contains 
six conserved cysteine residues, restraining the peptide in a tertiary structure containing 
three disulfide bonded loops (Wingens et al., 2003). 
EGF-like ligands are synthesized as transmembrane precursors which are subject to 
proteolytic cleavage at the cell surface to produce the soluble and diffusible growth factors 
(Massague and Pandiella, 1993). Subsequently, the mature ligands activate RTKs of the 
EGFR family by autocrine or paracrine stimulation. In addition, several studies indicate 
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that the membrane-anchored precursors may be biologically active via juxtacrine 
stimulation (Brachmann et al., 1989; Wong et al., 1989). 
Biophysical investigations revealed a 2:2 stoichiometry for ligand-receptor complexes 
generated from stable 1:1 ligand-receptor intermediates. As recent studies support, ligand 
binding leads to conformational changes in the receptor and therefore to subsequent 
formation of various homo- and heterodimers rather than to the bridging of receptor 
monomers by ligand molecules (Jorissen et al., 2003; Schlessinger, 2002). Receptor 
dimerisation was shown to occur entirely receptor-mediated by a motif termed the 
"dimerisation-loop" which is unique to the EGFR family of RTKs since deletions or 
mutations in this motif entirely abrogate ligand-induced EGFR activation (Garrett et al., 
2002; Ogiso et al., 2002). The dimerisation arm only becomes exposed after ligand binding 
as a consequence of a domain rearrangement in the extracellular portion of the EGFR 
thereby regulating receptor function. HER2, which has no ligand of its own, has been 
shown to constitutively adopt an extended configuration with an exposed dimerisation arm 
(Cho et al., 2003; Garrett et al., 2003). Together with further biophysical studies indicating 
only weak homodimeric interaction of HER2 receptor molecules, this observation suggests 
that HER2 mainly forms heterodimers with the remaining ligand-activated EGFR family 
members (Garrett et al., 2002), thus providing an additional platform for recruitment of 
intracellular signaling pathways. Figure 2 shows an overview over the preferred binding 
specificities of the EGF-like ligands and of HER2.   
 
 
 
Fig. 2. Binding specificities of the EGF-related peptide growth factors. There are four categories of 
ligands that bind ErbB family receptors. EGF, AR and TGF  bind ErbB1; BTC, HB-EGF and EPR bind 
ErbB1 and ErbB4; NRG-1 and NRG-2 bind ErbB3 and ErbB4; and NRG-3 and NRG-4 bind ErbB4.  
ErbB2 is the preferred dimerisation partner for the other ErbB receptors. Ligand binding to ErbB1 
(EGF), ErbB3 (NRG-1) or ErbB4 (NRG-1, BTC) induces the formation of receptor homodimers and ErbB2-
containing heterodimers. ErbB3 homodimers do not signal (indicated by the X), since the receptor has 
impaired kinase activity. Only some of the possible ligand–receptor-induced combinations are indicated in 
Figure 2 for the sake of simplicity (Olayioye et al., 2000). 
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The dimerisation of EGFR family members leads to intermolecular autophosphorylation of 
cytoplasmic tyrosine residues in the activation loop of the catalytic tyrosine kinase domain 
(Schlessinger, 2002) thereby leading to an open conformation of the activation loop. This 
enables access to ATP and substrate resulting in an enhanced tyrosine kinase activity and 
the subsequent recruitment of downstream signaling molecules.  
 
1.1.4 Cytoplasmic tyrosine kinases 
 
In addition to the membrane-anchored receptor tyrosine kinase, a second class of tyrosine 
kinase exists, the cytoplasmic non-receptor tyrosine kinase (NRTKs). The 32 NRTKs 
known so far are divided into 10 subfamilies based on their kinase domain sequence: Abl, 
Ack, Csk, Fak, Fes, Frk, Jak, Src, Tec and Syk (Blume-Jensen and Hunter, 2001; Robinson 
et al., 2000). 
NRTKs lack receptor-like features such as an extracellular ligand binding domain and a 
transmembrane-spanning region. NRTKs can bind to cell surface receptors, but many are 
localized in different intracellular compartments including the cytoplasm, the nucleolus, 
mitochondria and the endoplasmic reticulum. Furthermore, they can bind to the cell 
membrane through amino-terminal modifications, such as myristoylation and 
palmitoylation (Hantschel and Superti-Furga, 2004).  
The most common theme in NRTK regulation, as in RTK function, is tyrosine 
phosphorylation. In particular, phosphorylation of tyrosines in the activation loop of 
NRTKs, which occurs via trans-autophosphorylation or phosphorylation by a number of 
other NRTKs, leads to an increased enzymatic activity, whereas phosphorylation of 
tyrosines outside of the activation loop can negatively regulate kinase activity. In addition 
to the tyrosine kinase activity, NRTKs contain domains mediating protein-protein, protein-
lipid and protein-DNA interactions (Hubbard and Till, 2000). 
With nine members, the Src family is the largest subfamily of NRTKs and consists of Blk, 
Fgr, Fyn, Hck, Lck, Lyn, Src, Yes and Yrk (Blume-Jensen and Hunter, 2001). Src family 
members participate in a variety of signaling processes, including mitogenesis, T- and B-
cell activation and cytoskeleton remodeling. Various in vivo substrates have been described 
for Src including the platelet derived growth factor receptor (PDGFR) and the EGFR, the 
NRTK focal adhesion kinase Fak, the adapter protein p130Cas, which is involved in 
integrin- and growth factor-mediated signaling and cortactin, an actin-binding protein 
essential for the proper formation of cell matrix contact sites (Hubbard and Till, 2000). 
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Regulation of Src catalytic activity has been extensively studied. Src and its family 
members contain a myristoylated amino terminus, a stretch of positively-charged residues 
that interact with phospholipid head groups, a short region with low sequence homology, a 
SH3 domain, a SH2 domain, a tyrosine kinase domain, and a short carboxy-terminal tail. 
Src exhibits two important regulatory tyrosine phosphorylation sites. Phosphorylation of 
Tyr-527 in the carboxy-terminal tail of Src by the NRTK Csk represses kinase activity. 
The importance of this phosphorylation site is emphasized in v-Src, an oncogenic variant 
of Src which is a product of the Rous sarcoma virus. Because of a carboxyterminal 
truncation, v-Src lacks the negative regulatory site Tyr-527 and is constitutively active, 
resulting in uncontrolled growth of infected cells. A second regulatory phosphorylation site 
in Src is Tyr-416, an autophosphorylation site in the activation loop. Maximum stimulation 
of kinase activity occurs when Tyr-416 is phosphorylated. Src has also been implicated in 
several human carcinomas, including breast, lung and colon cancer (Biscardi et al., 1999).  
 
1.1.5 RTK downstream signaling and protein interaction domains 
 
Ligand-induced RTK activation induces specific intracellular signal transduction 
pathways, depending on the stimulus and the cellular context. To regulate many different 
cellular processes, most proteins involved in intracellular signaling contain modular 
protein domains that specifically interact with other protein domains, lipids, and nucleic 
acids. These interaction domains either target proteins to a specific subcellular localization, 
provide means of recognition for posttranslational protein modification or chemical second 
messengers. Furthermore, they can control the conformation, activity and substrate 
specificity of enzymes (Pawson and Nash, 2003).   
The most important domains in RTK signaling are those which recognize the 
phosphorylated tyrosine itself (Schlessinger and Lemmon, 2003). Phosphotyrosine residues 
are recognized by Src homology 2 (SH2) and phosphotyrosine binding (PTB) domains 
with SH2 representing the most prevalent binding domain (Schlessinger, 2000). PTB 
domains are not restricted to bind phosphotyrosine residues, because they can also bind to 
non-phosphorylated peptide sequences.  
WW and 14-3-3 domains bind to phosphoserine, while phosphothreonine residues are 
recognized by FHA and WD40 domains. The proline-rich sequence motif PXXP represents 
an additional binding moiety which binds specifically to SH3 domains. Pleckstrin 
homology (PH), phox homology (PHOX), FERM and FYVE domains bind to 
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phosphoinositides. Figure 3 shows an overview of different interaction domains and their 
binding specificities.  
 
 
 
Fig. 3. Modular interaction domains in signal transduction. Interaction domains bind proteins, 
phospholipids, or nucleic acid. A subset of such domains is illustrated and their general binding functions are 
indicated (Pawson and Nash, 2003). 
 
A wide variety of proteins possesses both, an interaction domain and enzymatic activity. In 
addition to their SH2 domain, Src kinases have a protein kinase activity and PLC-γ a 
phospholipase C activity. But some signaling proteins exclusively consist of SH2 and SH3 
domains, such as Grb2, Crk and SHC linking activated RTKs to downstream signaling 
events such as the mitogen-activated protein kinase (MAPKs).  
The ability of RTKs to recruit and activate a wide variety of adaptor proteins provides a 
signaling platform for the cell to regulate miscellaneous biological responses. 
  
1.2 Mitogen-activated-protein-kinase (MAPK) pathways 
 
Mitogen-activated protein kinases (MAPKs) are important signal transducing enzymes in 
the pathway connecting cell surface receptors to regulatory targets within the cell. MAPKs 
phosphorylate specific serine and threonine residues of target proteins and are implicated 
in cell migration, invasion, proliferation, differentiation, transformation and survival as 
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well as in angiogenesis. At least four differently regulated subgroups of MAPKs are 
present in mammals, extracellular-regulated kinase 1/2 (ERK1/2), Jun amino-terminal 
kinase (JNK1/2/3), p38 proteins (p38 α/β/γ/δ) and ERK 5 (Chang and Karin, 2001).  
The major function of the MAPK pathway is the regulation of gene expression either by 
direct phosphorylation of transcription factors, target co-activators or co-repressors (Yang 
et al., 2003). 
The most prominent MAPK pathway is the cascade leading to activation of ERK 1/2 by 
RTKs. Upon ligand-induced activation of RTKs, the adaptor protein Grb2 is recruited. 
Grb2 associates with the RAS-GEF Sos complex thereby activating it, which in turn 
activates membrane-associated Ras, a small monomeric GTP-binding protein 
(Schlessinger, 2000).  Activated Ras interacts with several effector proteins such as the 
MAPK kinase kinase (MAPKKK) Raf-1 and PI3-K to stimulate numerous intracellular 
processes. Activated Raf-1 sequentially stimulates the MAPK kinases 1/2 (MAPKK, MEK 
1/2) by phosphorylating a key serine residue in the activation loop. In the following, MEK 
1/2   phosphorylates MAPK on threonine and tyrosine residues in regulatory TEY-motif 
leading to its activation (Robinson and Cobb, 1997). Activated MAPK phosphorylates a 
variety of cytoplasmic and membrane linked substrates. For example, it influences the 
transmembrane protein processing of ADAM17 by phosphorylation of the intracellular 
domain (Diaz-Rodriguez et al., 2002; Fan and Derynck, 1999). In addition, MAPK is 
rapidly translocated into the nucleus where it phosphorylates and activates transcription 
factors. The signaling cassette composed of MAPKKK, MAPKK, and MAPK is highly 
conserved in evolution and plays an important role in the control of metabolic processes, 
cell cycle, cell migration and cell shape as well as in cell proliferation and differentiation 
(Hunter, 2000). 
The specificity of MAPK interactions and of the effector molecules stimulated depends 
largely on the MAPK subtypes involved. In particular, extracellular signal-regulated 
kinases (ERK1/2)/MAPKs are primarily stimulated by growth factors and modulate cell 
growth and differentiation, whereas c-Jun N-terminal kinases (JNKs) and p38 MAPKs are 
most commonly activated by stress stimuli and are involved in cell growth, differentiation, 
survival, apoptosis, and cytokine production (Marinissen and Gutkind, 2001). 
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1.3 Protein kinase B (PKB)/Akt 
 
In mammals three isoforms, Akt 1, 2 and 3, of the serine/threonine kinase PKB/Akt are 
present, which are structurally closely related. They are composed of three functionally 
distinct regions, an N-terminal pleckstrin homology (PH) domain, a central catalytic 
domain and a C-terminal hydrophobic motif (HM). 
Protein kinase B is activated by the phosphoinositide 3-kinase (PI3-K) pathway. 
Generation of PIP3 and PIP(3,4)P2 is necessary for recruitment of PKB to the membrane 
surface. Activation takes place by multisite phosphorylation, but the main phosphorylation 
site is Threonine 308. The fully activated multiphosphorylated PKB then dissociates from 
the plasma membrane and targets substrates located in the cytoplasm and nucleus leading 
to the activation of genes involved in diverse cellular processes. Furthermore, deregulated 
PKB activation is known to contribute to tumor development and metastasis as well as 
chemotherapeutic resistance (Hanada et al., 2004; Nicholson and Anderson, 2002).  
 
1.4 G protein coupled receptors 
 
The cell surface superfamily of G protein coupled receptors (GPCRs) forms one of the 
largest protein family and, with more than 1000 family members, represents up to 1% of 
the total genome of mammalians (Hermans, 2003). GPCRs are involved in diverse 
physiological functions including neurotransmission, photoreception, chemoreception, 
metabolism, growth and differentiation (Fukuhara et al., 2001). A diverse array of external 
stimuli including neurotransmitters, hormones, lipids, photons, odorants, taste ligands, 
nucleotides and calcium ions can act by binding to GPCRs and therefore induce diverse 
physiological functions as shown in Figure 4. 
GPCRs can be divided into three major families, the receptors related to rhodopsin (type 
A), receptors related to the calcitonin receptor (type B) and the receptors related to 
metabotropic recptors (type C) (Gether and Kobilka, 1998). 
Based on their highly conserved protein structure, GPCRs are also called heptahelical or 
serpentine receptors as they contain a conserved structural motif of seven α-helical 
membrane-spanning regions, each consisting of 20-27 amino acids. N-terminal segments, 
the cyto- and exoloops as well as the C-terminal segment can greatly vary in size. The 
amino-terminus is exposed to the extracellular environment and is believed to play a role in 
ligand binding for there exists a weak correlation between ligand size and the N-terminal 
1 Introduction 11
segment's length. Both the C-terminus and the intracellular loops interact with intracellular 
signaling partners, such as the associated heterotrimeric G proteins, but also with a wide 
variety of proteins containing structural interacting domains including PDZ, SH3 or PTB 
domains (Bockaert et al., 2003; Ji et al., 1998).  
 
 
Fig. 4. Diversity of G protein coupled receptors (GPCRs). A wide variety of ligands, including biogenic 
amines, amino acids, ions, lipids, peptides and proteins, use GPCRs to stimulate cytoplasmic and nuclear 
targets through heterotrimeric G protein dependent and independent pathways. Such signaling pathways 
regulate key biological functions such as cell proliferation, cell survival and angiogenesis. Abbreviations: 
DAG, diacylglycerol; FSH, follicle-stimulating hormone; GEF, guanine nucleotide exchange factor; LH, 
leuteinizing hormone; LPA, lysophosphatidic acid; PAF, platelet-activating factor; PI3K,  
phosphoinositide 3-kinase; PKC, protein kinase C; PLC, phospholipase C; S1P, sphingosine-1-phosphate; 
TSH, thyroid-stimulating hormone (Marinissen and Gutkind, 2001).  
To add yet another layer of complexity, dimers or higher oligomers among identical 
GPCRs, close family members, or GPCRs from different families influence ligand binding, 
receptor activation, desensitization, trafficking and receptor signaling (Breitwieser, 2004) 
 
1.4.1 Heterotrimeric G-proteins 
 
A common biochemical characteristic of GPCRs is their interaction and activation of 
downstream signaling cascades by heterotrimeric G proteins, although some studies 
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reported G protein independent signaling through some GPCRs (Bockaert and Pin, 1999; 
Hall et al., 1999). 
Heterotrimeric G proteins are composed of a Gα subunit interacting with a Gβγ subunit. 
Ligand binding to GPCRs alters the conformation of intracellular receptor domains and 
induces the association with heterotrimeric G proteins. This results in an exchange of GDP 
for GTP in the active site of the Gα subunit, followed by the dissociation of the 
heterotrimeric complex. Both the Gα and Gβγ subunits activate cytoplasmic or membrane 
bound effector molecules (Hermans, 2003).  
The specific and complex signaling induced by GPCRs is due to the existence of at least 
23 Gα subunits derived from 17 different genes, 6 Gβ and 12 different Gγ subunits.              
G proteins are generally referred to by their Gα subunits, which are subdivided on the basis 
of amino acid similarities in four distinct families, namely Gαs, Gαq, Gαi and Gα12 
(Hermans, 2003; Pierce et al., 2001).  
On the other hand, the number of downstream effectors is comparably limited and many            
G proteins couple to the same intracellular effectors. Effectors comprise adenylyl and 
guanylyl cyclase, calcium channels, GTPase-activating proteins (GAPs),  
guanine-nucleotide exchange-factors (GEFs), c-Src tyrosine kinase, phosphodiesterase and 
phospholipases. By this means, the signaling cascades induced by activated G proteins 
influence the level of second messengers like cyclic AMP and cyclic GMP, diacylglycerol, 
inositol (1,4,5)-triphosphate, phosphatidyl inositol (3,4,5)-triphosphate or calcium levels 
(Marinissen and Gutkind, 2001; Pierce et al., 2001) 
 
1.4.2 Mitogenic GPCR signaling 
 
Many reports suggest GPCRs to induce mitogenic responses and to be involved in the 
regulation of pathologic proliferation. Potent mitogens such as acetylcholine, angiotensin, 
bombesin, bradykinin, endothelin-1, isoproterenol, lysophosphatidic acid (LPA), 
neurotensin, prostaglandin and thrombin have been shown to induce mitogenic responses 
in tissue culture systems (Daaka, 2004).  
The discovery of the mas oncogene, whose protein product displays a heptahelical 
structure, first revealed a connection between GPCRs and cellular transformation (Young 
et al., 1986). Furthermore, several known oncogenes encode mutated forms of GPCRs or 
their associated G proteins. Activating mutation of the α1B-adrenoreceptor,  thyroid-
stimulating hormone receptors and luteinizing hormone receptors even in an agonist-
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independent manner have been detected in adenoma of the thyroid and hyperplastic 
Leydig's cells, respectively (Marinissen and Gutkind, 2001; Parma et al., 1993; Shenker et 
al., 1993). In addition, the genomes of various transforming viruses such as Kaposi's 
sarcoma-associated herpesvirus contain sequences encoding constitutive active GPCRs 
shown to induce cancer in animal models (Montaner et al., 2003). Activating mutants of 
Gα subunits encoding transforming oncogenes such as gsp, gip2 and gep are described 
(Dhanasekaran et al., 1998; Landis et al., 1989; Lyons et al., 1990; Marinissen and 
Gutkind, 2001; Radhika and Dhanasekaran, 2001; Xu et al., 1993).  
Moreover, ectopically expressed GPCRs such as muscarinic acetylcholine M1, M2, and M5 
receptors could transform fibroblasts dependent in an agonist-dependent manner, 
suggesting that endogenous GPCRs can be tumorigenic when persistently simulated by 
agonists released from tumors in an autocrine or paracrine fashion. Inhibiting the function 
of GPCRs effectively prevents tumor growth in animal models leading to the possibility to 
develop novel therapeutics for cancer intervention which act on GPCRs. 
 
1.4.3 The LPA receptors Edg 2, 4 and 7 
 
LPA is an extracellular lipid mediator produced by activated platelets or from circulating 
lysophosphatidylcholine by autotoxin and has been implicated in the regulation of both, 
physiological and pathophysiological processes (Brindley, 2004; Fang et al., 2000a; 
Moolenaar et al., 1997). LPA represents the major mitogenic activity in serum and 
numerous cellular responses to LPA have been documented including rapid cytoskeletal 
rearrangements (Gohla et al., 1998), stimulation of cell proliferation (van Corven et al., 
1989), suppression of apoptosis (Fang et al., 2000b) and induction of tumor cell migration 
and invasion (Fishman et al., 2001; Imamura et al., 1993). LPA levels are elevated in 
plasma and ascites of ovarian cancer patients (Fishman et al., 2001; Imamura et al., 1993; 
Xu et al., 1995; Xu et al., 1998) and LPA is likely to play a prominent role in the pathology 
of other types of human cancer.  
Recently, cell surface receptors for LPA and the structurally related phospholipids 
sphingosine-1-phosphate (S1P) have been identified as members of the Edg (endothelial 
cell differentiation gene) subfamily of GPCRs (Kranenburg and Moolenaar, 2001) (Pyne 
and Pyne, 2000). Four LPA receptors, Edg2 (An et al., 1997), Edg4 (An et al., 1998a; 
Contos and Chun, 2000) and Edg7 (Bandoh et al., 1999) as well as five S1P receptors, 
Edg1, Edg3, Edg5, Edg6 and Edg 8 have been described which couple to various subtypes 
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of G proteins and show distinct characteristics in ligand specificity and activation of 
intracellular signaling pathways (Takuwa et al., 2002). Very recently, a fourth LPA 
receptor GPR23 has been identified which is structurally different from the Edg receptors 
(Noguchi et al., 2003). 
The LPA receptors exhibit a high homology and are widely expressed (Figure 5). 
Overlapping expression patterns and the lack of subtype-specific agonists complicate the 
efforts to assign subtype specific physiological functions. Additionally, LPA can act 
independently of its receptors (Hooks et al., 2001). Recent studies on knock-out mice, 
however, have unveiled redundant as well as non-redundant functions for the LPA 
receptors that are essential for normal development and vascular maturation (Contos et al., 
2002; Takuwa et al., 2002).  
 
 
 
Fig. 5. Properties of lysophospholipid receptor genes. The dendrogram is based on percentage of amino 
acid identities among mouse LP receptor sequences (except lpB4, which is from rat) and shows the predicted 
evolutionary divergence of the genes. Common synonyms are indicated in parentheses, and mouse gene 
symbols are denoted with asterisks. Probable G protein partners for each of the encoded receptors are shown, 
based on receptor expression studies that indicate PTX-sensitive cellular responses (Gi/o coupling), PTX-
insensitive cytoskeletal rearrangement/ Rho activation (G12/13 coupling), or PTX-insensitive intracellular 
calcium mobilization and/or inositol phosphate production (Gq coupling) (Contos et al., 2000).  
 
According to the cellular context, LPA is shown to be involved in the modulation of 
adenylate cyclase, stimulation of phospholipase C (PLC) and subsequent Ca2+ 
mobilization, phosphorylation of the survival mediator Akt/protein kinase B (PKB) by  
PI3-K and transcriptional regulation of immediate-early genes (Kranenburg and 
Moolenaar, 2001; Moolenaar, 1999; Moolenaar et al., 1997; Pyne and Pyne, 2000). 
Additionally, LPA stimulation leads to Rho induced stress fiber formation and cell 
rounding  and activation of the Ras/MAPK pathway (Contos et al., 2000) (Figure 6). The 
latter pathway is connected to the induction of DNA synthesis and cellular proliferation.  
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Fig. 6. G protein coupled receptor signal transduction pathways activated by LPA. Lines with 
arrowheads illustrate activation paths, whereas inhibition effects are illustrated by lines with crossbars. 
Sequential arrows indicate multiple signaling steps that are not illustrated. Activation of Gi/o inhibits AC and 
thus cAMP production. This pathway also activates the Ras-MAP kinase (MAPK) cascade, which is 
primarily responsible for increased proliferation. In addition, Gi/o activates PLC via its βγ subunits, which 
results in generation of diacylglycerol (DAG) and inositol triphosphate (IP3) from phosphatidylinositol 
diphosphate (PIP2). DAG activates protein kinase C (PKC), and IP3 mobilizes [Ca2+]i. All Gi/o-mediated 
signaling is specifically inhibited by PTX. G12/13 proteins are responsible for activation of the small GTPase, 
Rho, which can be specifically inhibited by Botulinum C3 exoenzyme (C3). Activated Rho stimulates Rho 
kinases, inducing cytoskeletal and morphological changes. Rho kinases are directly inhibited by Y-27632. 
The α subunits of Gq proteins are the primary effectors of PLC activation (Contos et al., 2000).  
 
In many cellular systems, transactivation of the EGFR is reported to be mediated by LPA. 
Since LPA is one of the most potent mitogens known so far and implicated to be involved 
in the development and progression of many types of cancer, the mechanism leading to the 
LPA receptor induced activation of the Ras-MAPK pathway is of uppermost interest for 
the prevention of cancer development.  
 
1.5 EGFR signal transactivation 
 
In 1996, Daub et al. identified the EGFR as an essential element in GPCR-induced 
mitogenesis of rat fibroblasts (Daub et al., 1996). Upon treatment of cells with the G 
protein-coupled receptor agonists lysophosphatidic acid (LPA), endothelin-1 (ET-1) and 
thrombin, the EGFR and its relative HER2 were found to be rapidly tyrosine-
1 Introduction 16
phosphorylated. This transactivation of a receptor tyrosine kinase couples GPCR ligands to 
ERK 1/2 activation and induction of c-fos gene expression.  
Further investigations revealed that GPCR-EGFR crosstalk pathways are established in a 
variety of other cell types such as human keratinocytes, primary mouse astrocytes, PC12 
cells and vascular smooth muscle cells and established them as widely relevant towards the 
activation of the MAPK signal (Fischer et al., 2003; Gschwind et al., 2001; Hart, 2003). In 
addition, preincubation of COS7 cells with pertussis toxin blocked LPA-induced EGFR 
signal transactivation, implicating the involvement of Gα subunits of the Gαi/o family of G 
proteins (Daub et al., 1997). Interestingly, EGFR transactivation was also observed after 
agonist stimulation of ectopically expressed Gαq coupled bombesin receptor (BombR) or 
Gαi coupled M2 muscarinic acetylcholine receptor (M2R) indicating that various  
Gα subunits of the G proteins are involved in transactivation of the EGFR depending on 
the stimulus and the cellular context. 
Due to the rapid onset of GPCR-induced EGFR tyrosine phosphorylation and the fact that 
EGF-like ligands were not detectable in cell culture medium after G protein activation, the 
transactivation mechanism was postulated to exclusively rely on intracellular elements 
(Daub et al., 1996; Zwick et al., 1999). Different cytoplasmic tyrosine kinases,  
Ser/Thr kinases such as PKC and second messengers have been discussed as potential 
mediators of the transactivation signal. Src-family kinases have been suggested both as 
upstream and downstream mediators of GPCR induced EGFR transactivation. However, 
several studies indicated that the EGFR transactivation mechanism is subject to different 
cell type-characteristic regulatory influences. In different cellular systems EGFR activation 
was reported to involve intracellular calcium levels and the Ca2+-regulated tyrosine kinase 
Pyk2 (Eguchi et al., 1998; Keely et al., 2000; Murasawa et al., 1998; Soltoff, 1998; 
Venkatakrishnan et al., 2000; Zwick et al., 1997). 
In contradiction to a ligand-independent mechanism, it was reported that a chimeric RTK 
consisting of the ligand-binding domain of the EGFR and the transmembrane and 
intracellular portion of the PDGFR, was transactivated upon treatment of Rat1 fibroblasts 
with GPCR ligands resulting in a PDGFR-characteristic intracellular signal (Prenzel et al., 
1999). These findings suggested a critical function of the EGFR extracellular domain in the 
GPCR-EGFR cross-talk mechanism, as the PDGFR was not tyrosine phosphorylated upon 
treatment of Rat1 cells with GPCR ligands. Furthermore, a system of co-cultured cell lines 
stably expressing either the M1R or the human EGFR resulted in intercellular EGFR 
transactivation after carbachol stimulation. In addition, LPA-, carbachol- or tetra-decanoyl-
phorbol-13-acetate (TPA) induced transactivation of the EGFR and tyrosine 
1 Introduction 17
phosphorylation of SHC were completely abrogated by the diphtheria toxin mutant 
CRM197 that specifically blocks proHB-EGF function or the metalloprotease inhibitor 
batimastat (BB94) in COS7 and HEK 293 cells. Flow cytometric analysis directly 
confirmed cell-surface ectodomain shedding of proHB-EGF upon treatment with GPCR 
agonists or TPA. 
These data supported the concept of a "Triple-Membrane-Passing-Signal" (TMPS) 
mechanism of EGFR signal transactivation involving a metalloprotease activity and 
processing of the transmembrane EGF-like growth factor precursor proHB-EGF (Prenzel 
et al., 1999). In this regard, growing evidence indicated transmembrane metalloproteases 
as the key enzymes of growth factor precursor shedding. The metalloprotease inhibitor 
batimastat (BB94) was shown to inhibit bombesin- and TPA-induced transactivation of the 
EGFR in PC-3 human prostate cancer cells and to reduce high constitutive levels of EGFR 
tyrosine phosphorylation in unstarved PC3 (Prenzel et al., 1999) and SCC25 squamous cell 
carcinoma cells (Gschwind et al., 2002). Furthermore, Dong and colleagues reported that 
BB94 reduced cell proliferation and cell migration of an human mammary epithelial cell 
line by interfering with the release of EGFR ligands (Dong et al., 1999). BB94 also 
inhibited proliferation of colon and breast cancer cell lines which were known to depend 
on autocrine signaling through the EGFR. Recently, Gschwind and colleagues showed that 
LPA-induced proliferation and motility of head and neck cancer cells involves 
metalloprotease-dependent transactivation of the EGFR (Gschwind et al., 2002). Various 
studies have identified members of the ADAM subclass of metalloproteases to play a 
critical role in GPCR mediated transactivation of the EGFR (Gschwind et al., 2003; Sahin 
et al., 2004). This lead to the following updated model of the triple membrane passing 
signal mechanism of EGFR signal transactivation (Figure 7).  
Since the initial discovery of this mechanism, many studies demonstrated the broad 
relevance of said signaling mechanism within a variety of cellular systems and, 
importantly, the involvement in development and progression of pathophysiological 
processes. Moreover, EGFR function was reported to be critical for GPCR stimulated 
mitogenic signaling in several cancer cells (Castagliuolo et al., 2000; Venkatakrishnan et 
al., 2000). 
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Fig. 7. The triple-membrane-passing signal (TMPS) mechanism of EGFR transactivation. GPCR 
stimulation induces upregulation of a metalloprotease activity, therby leading to ectodomain cleavage of 
EGF-like growth factor precursors. Subsequent release of the mature growth factor stimulates EGFR kinase 
activity and transduces the GPCR signal inside the cell to stimulate characteristic EGFR downstream 
signaling pathways such as MAPK, PLC-γ, STAT or PI3K activation (Fischer et al., 2003). 
 
In addition to EGFR transactivation, other RTKs such as the insulin-like growth factor 
receptor (IGF-1R), hepatocyte growth factor receptor (Met-R), vascular endothelial cell 
growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and the 
Fibroblast growth factor receptor (FGFR)-1 have been shown to be activated by GPCR 
agonists (Belcheva et al., 2001; Endo et al., 2002; Fischer et al., 2004; Herrlich et al., 1998; 
Pai et al., 2003; Weiss et al., 1997).  
 
1.6 Metalloproteases 
 
Metalloproteases are important for many biological processes, ranging from cell 
proliferation, differentiation and remodelling of the extracellular matrix (ECM) to 
vascularization and cell migration. These events occur several times during organogenesis, 
in both normal development and during tumour progression. Mechanisms of 
metalloprotease action include the proteolytic cleavage of growth factors so that they 
become available to cells not in direct physical contact, degradation of the ECM enabling 
founder cells to move across tissues into nearby stroma and regulated receptor cleavage to 
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terminate migratory signaling. Most of these processes require a sensitive balance between 
the functions of matrix metalloproteases (MMPs) or metalloprotease-disintegrins 
(ADAMs) and natural tissue inhibitors of metalloproteases (TIMPs). 
Proteases of the zinc protease superfamily are classified according to the primary structure 
of their catalytic sites including carboxypeptidase, DD carboxypeptidase, gluzincin, 
inuzincin and metzincin subgroups (Hooper, 1994). The metzincins are further subdivided 
in adamalysins, astacins, matrixins and serralysins (Bode et al., 1993).  
For the hydrolytic processing of substrates, the active site of zinc metalloproteases contains 
water ions and zinc which is coordinated by three conserved histidine residues and a 
downstream methionine. The methionine constitutes a Met turn motif that loops around to 
face the consensus HEXXHXXGXXH site. The glutamic acid is believed to transfer 
hydrogen atoms and to polarize the zinc-bound water molecule for nucleophilic attack on 
the scissile peptide bond of bound substrate (Stocker and Bode, 1995).  
Many metalloproteases are synthesized as inactive precursors containing a terminal 
prodomain which keeps the metalloprotease site inactive by a cysteine switch (Becker et 
al., 1995). Besides its role as an inhibitor of the protease domain, the prodomain appears to 
be important for maturation and intracellular transport of metalloproteases (Milla et al., 
1999). The processing and activation of metalloproteases by furin, other proprotein 
convertases (PCs) or autocatalytic are proposed to occur at the trans-Golgi network 
(Anders et al., 2001; Kang et al., 2002). 
  
1.6.1 ADAMs 
 
Metalloprotease-disintegrins are transmembrane glycoproteins which take part in cell-cell 
interaction and in processing of protein ectodomains (Wolfsberg et al., 1995). They 
combine features of both cell surface adhesion molecules and metalloproteases and are 
characterized by a conserved domain structure consisting of a N-terminal signal sequence 
followed by a prodomain, metalloprotease and disintegrin domains, a cysteine-rich region 
and finally a transmembrane domain and cytoplasmic tail (Figure 8). Thus, family 
members are referred to as ADAM (a disintegrin and metalloprotease domain) or as MDCs 
(metalloprotease, disintegrin, cysteine-rich proteins). 
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Fig. 8. The topography of the ADAMs and related metalloproteases. Generalized domain structures of 
the ADAMs, SVMPs, ADAM-TS, and MMP families are shown. Note that ADAM-TS family members have 
a variable number of thrombospondin-like (TS) motifs. The MMP shown is of the gelatinase class. Other 
subclasses of MMPs lack hemopexin-like sequences and/or fibronectin type II-like sequences. The subclass 
of MT-MMPs has transmembrane domains and cytoplasmic tails in addition to the domains shown (Seals and 
Courtneidge, 2003). 
  
More than 30 ADAM cDNA sequences have been identified in organisms ranging from S. 
pombe to humans up to date (Primakoff and Myles, 2000). Although all ADAMs have a 
relatively well-conserved metalloprotease domain, only 15 contain the zinc-binding 
catalytic-site consensus sequence (HEXXH). Therefore, only 50 percent of the known 
ADAMs are predicted to be catalytically active. ADAMs have been implicated in diverse 
processes, including sperm-egg binding and fusion, membrane fusion, protein-ectodomain 
processing or shedding of cytokines, cytokine receptors, adhesion proteins and RTKs and 
growth factor precursors (Kheradmand and Werb, 2002; Schlondorff and Blobel, 1999).  
The disintegrin domain of ADAMs allows the interaction with integrin receptors, but not 
all ADAM proteases have the RGD sequence in their disintegrin loop (Blobel and White, 
1992). In contrast, the cysteine-rich and EGF-like domains are not well characterized, but 
it is believed that the cysteine rich domain supplements the binding capacity of the 
disintegrin domain. Cancer cells are shown to interact with cell surface heparin-sulfate 
proteoglycans in an in vitro binding assay with the cysteine-rich domain of ADAM12 
serving as a ligand for the cell-adhesion molecule syndecan (Iba et al., 2000; Iba et al., 
1999).  
The cytoplasmic tails of proteases of the ADAM family vary both in length and in the 
protein sequence and contain motifs like PXXP binding sites for SH3 domain-containing 
proteins or potential phosphorylation sites for serine-threonine and/or tyrosine kinases. 
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Many studies postulate that the cytoplasmic tail is involved in maturation and regulation of 
metalloprotease activity. 
The regulation of ADAM metalloprotease activity after prodomain removal is only poorly 
understood. Processing of membrane proteins by ADAMs requires both the membrane-
anchored enzyme and its substrate to be present in cis on the same cell, probably anchored 
in distinct domains of the plasma membrane through cytoskeletal interactions. Upon cell 
activation, for example by PKC agonists, increases in cytoplasmic Ca2+ levels or tyrosine 
kinase stimulation, the attachments change and the proteases and substrates become co-
clustered and can interact (Werb and Yan, 1998). Alternatively, the signaling cascade 
could modify the cytoplasmic domains of the proteases or substrate, producing a 
conformational change that either activates the enzyme or makes the cleavage site 
available (Schlondorff and Blobel, 1999). For most processing reactions there appears to 
be a constitutive level of ectodomain shedding. Processing is necessary to make paracrine 
growth and survival factors available including EGF-like ligands allowing for the 
consistent supply of EGFR agonists.  
Tumor necrosis factor-α convertase (TACE/ADAM17) is the best characterized 
metalloprotease and has been identified as the protease responsible for the release of the 
inflammatory cytokine tumor necrosis factor (TNF)-α from its membrane-bound precursor 
proTNFα (Black et al., 1997; Moss et al., 1997). Besides TNFα, ADAM17 mediates 
cleavage of diverse integral membrane proteins like L-selectin, p75 TNF receptor (Peschon 
et al., 1998), fractalkine (Garton et al., 2001), MUC1 (Thathiah et al., 2003), β-amyliod 
precursor protein (βAPP) (Buxbaum et al., 1998), p55 TNFR, interleukin-1 receptor II (IL-
1R II) (Reddy et al., 2000), erbB4/HER4 (Rio et al., 2000), the Notch1 receptor (Brou et 
al., 2000), IL-6R (Althoff et al., 2000), growth hormone-binding protein (Zhang et al., 
2000) and cellular prion protein (Vincent et al., 2001). Studies using fibroblasts derived 
from ADAM17 knock-out mice implicated ADAM17 in the release of TGFα and other 
EGF-like ligands as well as the constitutive availability of these growth factors (Peschon et 
al., 1998; Sunnarborg et al., 2002). Mice with tace∆Zn/∆Zn null mutation die at birth with 
phenotypic defects, including failure of eyelid fusion, hair and skin defects, and 
abnormalities of lung development (Shi et al., 2003). The epithelial defects observed in 
tace∆Zn/∆Zn fetuses are similar to those reported in mice lacking the epidermal growth factor 
receptor (EGFR) (Peschon et al., 1998). Abrogation of ADAM17 function in mice leads to 
perinatal lethality which is not seen in EGFR or TGFα deficient mice, indicating that 
ADAM17 has additional substrates required for the development of important organs 
which are necessary for survival (Shi et al., 2003).  
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1.6.2 The matrix metalloproteinases (MMPs) 
 
Matrix metalloproteinases (MMPs) are closely related to the ADAM family of 
metalloproteases and play a central role in breakdown and remodeling of the extracellular 
matrix (ECM) (Shapiro, 1998). Therefore, they are essential for development, wound 
healing and are involved in the pathology of hyperproliferative diseases such as cancer and 
arthritis (Chang and Werb, 2001; Seals and Courtneidge, 2003).   
MMPs were historically divided into collagenases, gelatinases, stromelysins and 
matrilysins on the basis of their specificity for ECM components. However, a sequential 
numbering system for the more than 20 known human MMPs has been adapted and the 
MMPs are now classified according to their structure (Nagase and Woessner, 1999). There 
are eight distinct classes of MMPs: five are secreted and three are membrane-type MMPs 
(MT-MMPs). All MMPs are synthesized as prepro-enzymes and secreted as inactive pro-
MMPs in most cases. The prodomain has a conserved unique PRCG(V/N)PD sequence. 
The cysteine within this sequence coordinates the catalytic zinc to maintain the latency of 
pro-MMPs. The catalytic domains of MMPs have an additional structural zinc ion and 2-3 
calcium ions, which are required for the stability and the expression of enzymatic activity. 
The gelatinases MMP-2 and MMP-9 have three repeats of fibronectin-type II domain 
inserted in the catalytic domain. 
These repeats interact with collagens and gelatins. Most of the MMPs are activated outside 
the cell by other activated MMPs or furin-like serine proteases. Endogenous inhibitors 
such as α-macroglobulins and tissue inhibitors of metalloproteinases (TIMPs) tightly 
control the proteolytic activities of MMPs. Many reports identified TIMPs to inhibit cell 
invasion in vitro, tumorigenesis, metastasis in vivo and angiogenesis (Gomez et al., 1997). 
The expression of many MMPs is transcriptionally regulated by growth factors, hormones, 
cytokines and cellular transformation (Brinckerhoff and Matrisian, 2002). Furthermore, 
substrates of MMPs as well as of ADAMs are EGF-like growth factors like HB-EGF 
which leads to the assumption that MMPs are also involved in EGFR signal transactivation 
(Roelle et al., 2003; Suzuki et al., 1997; Yu et al., 2002). 
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1.7 Molecular oncology  
 
In normal cells cell division, survival and death are in balance promoting homeostasis. It is 
a general phenomenon in normal as well as transformed cells that signaling pathways are 
not freestanding entities but parts of larger signaling networks. Therefore, products of 
proto-oncogenes and tumor suppressor genes interact in overlapping pathways and 
dysfunction of the tightly controlled equilibrium leads to cancer.  
Cancer development is a multistage process involving genetic alterations that drive the 
progressive transformation of normal human cells into highly malignant derivatives 
(Hanahan and Weinberg, 2000). The genomes of tumor cells can be altered at multiple 
sites from subtle changes such as point mutations to severe changes in chromosome 
complement (Blume-Jensen and Hunter, 2001). Furthermore, cancer is the most common 
genetic disease: one in three people in the western world will develop cancer and one in 
five will die from it. Therefore, it is essential to elucidate the mechanisms behind the 
transformation of normal cells to cancer cells and the conversion of normal tissue into 
malignant tumors.  
Observations of human cancers and animal models suggest that tumor development 
proceeds via a process formally analogous to Darwinian evolution, in which a succession 
of genetic changes, each conferring one or another type of growth advantage, leads to the 
progressive conversion of normal human cells into cancer cells. The vast catalog of cancer 
cell genotypes is a manifestation of six essential alterations in cell physiology that 
collectively dictate malignant growth and which are now recognized as the six hallmarks 
of cancer: self-sufficiency in growth signals, insensitivity to growth-inhibitory (anti-
growth) signals, evasion of programmed cell death (apoptosis), limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis. It is assumed that 
these six properties are shared by most, if not all types of human tumors (Hanahan and 
Weinberg, 2000). 
Breast cancer belongs to the most frequent tumor types in women. HER2 overexpression 
or increased activity has been shown to be a genetic marker for a severe type of breast 
cancer with a poor diagnosis (Pegram et al., 1998; Slamon and Clark, 1988; Slamon et al., 
1987; Slamon et al., 1989).  In some carcinomas of the breast, overexpression of the EGFR 
was detected (Nicholson et al., 1991). Kidney cancer on the other hand, is more common 
in men and one of the most frequent tumors of the urogenital tract. Until today, the most 
effective treatment remains the complete removal of the affected organ and thus a severely 
impaired quality of life for the patient (Vogelzang and Stadler, 1998). Hence, there is a 
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strong need to identify novel intervention targets and to design patient-tailored therapies 
for prevention and treatment of these tumors. In order to reverse or at least contain tumor 
spreading it is of utmost importance to understand the molecular mechanisms underlying 
cancer development and progression.  
Benign tumors grow locally restricted, but the normal organization of the affected tissue 
gradually becomes disrupted by the increasing number of dividing cells. As the dividing 
cancer cells extend through the basement membrane into the surrounding stroma, 
malignancy begins. Invasion stimulatory pathways depend on the activation of G proteins, 
PI3-K and the Rac and Rho family of small GTPases. Proteolysis plays a role for the 
breakdown of extracellular matrix as well as cleavage of pro-invasive fragments from cell 
surface glycoproteins. As the dividing cancer cells extend into blood vessels, tumors 
undergo metastasis by spreading from the primary site to more distant sites in the body 
making cancer much more difficult to cure. 
 
1.8 Aim of the study 
 
Deregulation of both GPCR and EGFR signaling systems has been recognized as a major 
cause of hyperproliferative diseases. In addition, a pathway connecting these two classes of 
receptors has recently been discovered which entailed an arising research interest on this 
mechanism. 
The aim of this study was to elucidate the mechanisms underlying the EGF receptor 
transactivation signal induced by GPCR ligands as well as the pathophysiological role of 
this mechanism in breast and kidney cancer cells. 
A special interest of this study was the involvement of a certain class of GPCRs, the LPA 
receptors. LPA is one of the most potent mitogenic stimuli and therefore it is of great 
interest for tumor therapy to enlighten by which means LPA acts as a mitogen. It was 
necessary to establish appropriate model systems to study the direct influence of a single 
receptor on the transactivation signal as well as the biological responses.  
Another part of the study focused on the involvement of a certain metalloprotease, 
ADAM10, in the transactivation mechanism. This was performed in a model system which 
is known to involve ADAM10 in Thrombin induced EGFR transactivation. 
Since the signaling pathway connecting the GPCR to the metalloprotease was still 
unknown, multiple efforts have been taken to shed light on the molecular mechanism 
connecting these two parts of the pathway. GPCRs couple to heterotrimeric G proteins 
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which consist of a Gα and a Gβγ subunit. The involvement of these subunits was examined 
in different cellular systems.  
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2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 Laboratory chemicals and biochemicals 
 
Acrylamide       Serva, Heidelberg 
Agar        Difco, Detroit, USA 
Agarose       BRL, Eggenstein 
AG1478      Alexis, Grünberg    
Ampicillin      Roche, Mannheim 
Aprotinin      Sigma, Taufkirchen 
APS (Ammonium peroxodisulfate)    Bio-Rad, München 
ATP (Adenosine 3’-triphosphate)    Pharmacia, Freiburg 
Batimastat (BB94)     British Biotech, Oxford, UK 
Bisacrylamide      Roth, Karlsruhe 
Bromphenol blue      Sigma, Taufkirchen 
BSA (Bovine serum albumin)    Sigma, Taufkirchen 
CHAPS      Sigma, Taufkirchen 
Coomassie G250      Serva, Heidelberg 
Deoxynucleotides (dG/A/T/CTP)    Roche, Mannheim 
Dideoxynucleotides (ddG/A/T/CTP)   Pharmacia, Freiburg 
Diphtheria toxin CRM mutant   List Biological Lab., CA, USA 
DTT (Dithiothreitol)      Sigma, Taufkirchen 
Ethidium bromide      Sigma, Taufkirchen 
Fibronectin       Calbiochem, Bad Soden 
Heparin       Sigma, Taufkirchen 
HEPES (N-(2-Hydroxyethyl)piperazine-N'-  Serva, Heidelberg 
(2-ethanesulfonic acid)) 
IPTG (Isopropyl β-D-1-thiogalactopyranoside)  Biomol, Hamburg 
Ki16425      Kirin Laboratories, Tokyo 
L-Glutamine       Gibco, Eggenstein 
Lipofectamine®      Invitrogen, USA 
Lipofectamine 2000     Invitrogen, USA 
Lysozym      Sigma, Taufkirchen 
LY 294002      Alexis, Grünberg 
MBP (Myelin basic protein)     Sigma, Taufkirchen 
Mineral oil       Sigma, Taufkirchen 
Na-DOC (Sodium-desoxycholat)   Sigma, Taufkirchen 
Oligofectamine®     Invitrogen, USA 
PMSF (Phenylmethanesulfonyl fluoride)   Sigma, Taufkirchen 
Polybrene (Hexadimethrine bromide)   Sigma, Taufkirchen 
Ponceau S       Sigma, Taufkirchen 
PP1        Calbiochem, Bad Soden 
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PP2       Calbiochem, Bad Soden 
PTX (Pertussis toxin)     List Biological Lab., CA, USA 
Scintillation cocktail (Rotiszint®ecoplus)   Roth, Karlsruhe   
SDS (Sodium dodecyl sulfate)    Roth, Karlsruhe 
Sodium azide       Serva, Heidelberg 
Sodium fluoride      Sigma, Taufkirchen 
Sodium orthovanadate     Aldrich, Steinheim 
TEMED (N,N,N',N'-Tetramethylethylenediamine)  Serva, Heidelberg 
Triton X-100       Serva, Heidelberg 
Tween 20, 40      Sigma, Taufkirchen 
Tyrphostin AG1478      Alexis, Grünberg 
Wortmannin      Sigma, Taufkirchen 
Xylencyanol       
 
All other chemicals were purchased from Merck (Darmstadt). 
 
2.1.2 Enzymes 
 
AMV reverse transcriptase    Roche, Mannheim 
Alkaline Phosphatase (CIAP)   Roche, Mannheim 
LA-Taq-DNA Polymerase    Takara, Japan 
Pfu-DNA Polymerase    Roche, Mannheim 
Restriction Endonucleases     Pharmacia, Freiburg 
Roche, Mannheim 
NEB, Frankfurt/ Main 
MBI Fermentas, St. Leon-Rot 
T4-DNA Ligase      Roche, Mannheim 
T7-DNA Polymerase     Pharmacia, Freiburg 
Taq-DNA Polymerase     Roche, Mannheim 
Takara, Japan 
Trypsin       Gibco, Eggenstein 
 
2.1.3 Radiochemicals 
 
[γ-32P] ATP   >5000 Ci/mmol 
[α-33P] dATP   2500 Ci/mmol 
 
All radiochemicals were obtained from PerkinElmer Life Sciences, Köln. 
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2.1.4 "Kits" and other materials 
 
Cell culture materials     Greiner, Solingen 
Nunclon, Dänemark 
Falcon, U.K. 
Cellulose nitrate 0.45 µm     Schleicher & Schüll, Dassel 
Concanavalin A-Sepharose® 4B   Sigma, Taufkirchen 
ECL Kit       PerkinElmer, Köln 
Glutathione-Sepharose     Pharmacia, Freiburg 
Hyperfilm MP      Amersham, USA 
Micro BCA Protein Assay Kit    Pierce, Sankt Augustin 
Parafilm       Dynatech, Denkendorf 
Polyprep® Chromatography columns  Biorad, München 
Protein A-Sepharose      Pharmacia, Freiburg 
Protein G-Sepharose      Pharmacia, Freiburg 
PuReTaq Ready-To-Go PCR Beads    Amersham Biosciences, Piscataway, NJ 
QIAquick Gel Extraction Kit (50)    Qiagen, Hilden 
QIAquick PCR Purification Kit    Qiagen, Hilden 
QIAGEN Plasmid Maxi Kit     Qiagen, Hilden 
Random-Primed DNA Labeling Kit    Pharmacia, Freiburg 
RNeasy Mini Kit      Qiagen, Hilden 
Sephadex G-50 (DNA Quality)    Pharmacia, Freiburg 
Sterile filter 0.22 µm, cellulose acetate   Nalge Company, USA 
Sterile filter 0.45 µm, cellulose acetate   Nalge Company, USA 
TOP10/P3 One Shot™      Invitrogen, USA 
Transwells       Schubert & Weiss, Munich 
Whatman 3MM      Whatman, USA 
 
2.1.5 Growth factors and ligands 
 
EGF (murine)      Toyoba, Japan 
LPA       Sigma, Karlsruhe 
Sphingosine 1-phosphate    UBI, Lake Placid  
Thrombin      Sigma, Karlsruhe 
 
All other growth factors and ligands were purchased from Sigma. 
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2.1.6 Media and buffers 
 
2.1.6.1 Media for E. coli bacteria 
 
LB-Medium   1.0 % Tryptone 
0.5 % Yeast extract 
1.0 % NaCl 
pH 7.2 
 
2xYT-Medium  1.6 % Tryptone 
1.0 % Yeast extract 
1.0 % NaCl 
pH 7.2 
 
When necessary the following antibiotics were added to the media after autoclavation: 
 
Ampicillin   100 µg/ml or 50µg/ml for 1/2 Amp/Tet selection 
Kanamycin   100 µg/ml 
Chloramphenicol  30 µg/ml 
Tetracyclin  10 µg/ml 
 
LB-plates additionally contained 1.5 % agar. 
 
2.1.6.2 Cell culture media 
 
All cell culture media and additives are from Gibco (Eggenstein), fetal calf serum (FCS) was 
purchased from Sigma and Gibco. 
Dulbecco's modified eagle medium (DMEM) supplemented with 4.5 mg/ml glucose, 2 mM L-
glutamine, 1 mM sodium pyruvate. 
Eagle's minimum essential medium (MEM) supplemented with 2 mM L-glutamine, 0.1 mM 
non-essential amino acids and 1 mM sodium pyruvate. 
RPMI 1640 medium supplemented with 2 mM L-glutamine and 1 mM sodium pyruvayte. 
Nutrient mixture F12 (HAM) supplemented with 2 mM L-glutamine and DMEM 
supplemented with 4.5 mg/ml glucose, 2 mM L-glutamine, 1 mM sodium pyruvate mixed 1:1. 
Freeze medium containing 90 % heat-inactivated FCS and 10 % DMSO. 
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2.1.7 Stock solutions and buffers 
 
Anode buffer     0.2 M Tris/ HCl, pH 8.9 
 
BBS (2x)      50 mM BES 
280 mM NaCl 
1.5 mM Na2HPO4
pH 6.96 (NaOH) 
 
Cathode buffer     0.1 M Tris/ HCl, pH 8.25 
0.1 M Tricine 
0.1 % (w/v) SDS 
 
CHAPS lysis buffer    50 mM HEPES, pH 7.5 
      150 mM NaCl 
      1 mM EDTA 
      10 % Glycerol 
      10 mM Na4P2O7
      10 mM CHAPS 
2 mM VaO5
10 mM NaF 
1 mM PMSF 
100 µg/l Aprotinin 
 
DNA loading buffer (6x)    0.25 % Bromphenol blue 
0.25 % Xylencyanol 
30.0 % Glycerol 
100.0 mM EDTA, pH 8.0 
 
HBS (2x)      46 mM HEPES, pH 7.5 
274 mM NaCl 
1.5 mM Na2HPO4
pH 7.0 
 
HNTG (1x)     20 mM HEPES, pH 7.5 
      150 mM NaCl 
      0.1 % Triton X-100 
      10 % Glycerin 
      10 mM Na4P2O7 
 
Gel buffer     3.0 M Tris/ HCl, pH 8.45 
      0.3 % (w/v) SDS 
   
Gluthation Elution buffer   50 mM Tris/ HCl, pH 8.0 
10 mM DTT 
15 Mm Glutathion, reduced 
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Laemmli buffer (2x)     187.5 mM Tris/ HCl, pH 6.8 
6.0 % SDS 
30.0 % Glycerol 
0.01 % Bromphenol blue 
5.0 % ß-Mercaptoethanol 
 
NET (1x)      150.0 mM NaCl 
5 mM EDTA 
50 mM Tris/HCl, pH 7.4  
0.05 % Triton X-100 
 
PBS (1x)     13.7 mM NaCl 
2.7 mM KCl 
80.9 mM Na2HPO4
1.5 mM KH2PO4, pH 7.4 (HCl) 
 
RIPA lysis buffer    1 % NP40 
      1 % Na-DOC 
0.1 % SDS 
150 mM NaCl 
10 mM NaPO4, pH 7.2 
2 mM EDTA 
5 mM β-Glycerophosphat 
4 mM VaO5
10 mM NaF 
1 mM PMSF 
100 µg/l Aprotinin 
1mM DTT 
 
RIPA rescue buffer    10 mM NaPO4, pH 7.2 
1 mM NaF 
20 mM NaCl 
5 mM β-Glycerophosphat 
2 mM VaO5
1 mM PMSF 
100 µg/l Aprotinin 
1mM DTT 
 
RSP-buffer     1x PBS 
      0.5 mM EDTA 
      100 µg/l Aprotinin 
1 mM PMSF 
0.5 mM DTT     
      
SD-Transblot      50.0 mM Tris/ HCl, pH 7.5 
40.0 mM Glycine 
20.0 % Methanol 
0.004 % SDS 
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Schagger sample buffer   4.0 % (w/v) SDS 
12.0 % (w/v) Glycerol 
50 mM Tris/ HCl, pH 6.8 
2.0 % (w/v) β-Mercaptoethanol 
0.01 % (w/v) Serva Blue G  
 
“Strip” buffer      62.5 mM Tris/ HCl, pH 6.8 
2.0 % SDS 
100 mM ß-Mercaptoethanol 
 
TAE (10x)      400 mM Tris/Acetate 
10 mM EDTA 
pH 8.0 (Acetic acid) 
 
TE10/0.1      10.0 mM Tris/ HCl, pH 8.0 
0.1 mM EDTA pH 8.0 
 
Tris-Glycine-SDS (10x)    248.0 mM Tris/ HCl, pH 7.5 
1918.0 mM Glycine 
1.0 % SDS 
 
Triton X-100 lysis buffer   50 mM HEPES, pH 7.5 
      150 mM NaCl 
      1 mM EDTA 
      10 % Glycerin 
      1 % Triton X-100 
10 mM Na4P2O7 
2 mM VaO5
10 mM NaF 
1 mM PMSF 
100 µg/l Aprotinin   
 
2.1.8 Bacteria strains (E. coli) 
 
E. coli  Description       Origin/ Reference 
 
DH5aF’  F’/endA1 hsd17 (rk-mk-) supE44 recA1   Genentech, 
gyrA (Nal)  thi-1 (lacZYA-argF)    San Francisco, USA 
 
TOP10/P3 F- mcrA ∆(mrr-hsdRMS-mcrBC) ф80lacZ∆M15 Invitrogen, USA 
∆lacX74 deoR recA1 araD139 ∆(ara-leu)7697     
galU galK rpsL endA1 nupG 
P3: KanR AmpR (am) TetR (am) 
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2.1.9 Cell lines 
 
Cell Line  Description       Origin/ Reference 
 
A498 Human kidney carcinoma cell line    Sugen Inc., CA, 
USA 
BT20 Human mammary adenocarcinoma   ATCC HTB-19 
BT549 Human mammary ductal carcinoma   ATCC HTB-122 
COS7 African green monkey, SV 40 transformed kidney Genentech, 
 Fibroblasts       San Francisco, USA 
HEK293  Human embryonic kidney fibroblasts, transformed  ATCC CRL-1573 
with adenovirus Typ V DNA 
HEK293EBNA Human embryonic kidney fibroblasts expressing  Invitrogen, USA 
 EBNA1 
HS 578T Human mammary carcinoma    ECACC HTB-126 
MDA-MB 231 Human mammary carcinoma    ATCC HTB-26 
NIH 3T3 Mouse fibroblasts, Clone 7     C. Sherr 
McA-RH7777 Rat hepatoma cell line     ATCC CRL-1601 
Phoenix E, A  Retrovirus producer cell lines for the generation of  Nolan, Stanford,  
helper free ecotropic and amphotropic retroviruses, USA 
based on HEK-293 
Rat1 Rat fibroblasts      Genentech,  
San Francisco, USA 
SCC9 Human squamous cell carcinoma of the tongue  ATCC CRL-1629 
 
All other cell lines were obtained from the American Type Culture Collection (ATCC, 
Manassas, USA) and grown as recommended by the supplier. 
 
2.1.10 Antibodies 
 
The following antibodies were used in immunoprecipitation experiments or as primary 
antibodies in immunoblot analysis. 
 
 
Antibody   Description/ Immunogen     Origin/ Reference 
 
ADAM10/Kuz Rabbit, polyclonal/ AA732-748 of human   Chemicon, Hofheim 
   ADAM10 
ADAM10 MP  Rabbit, polyclonal/ metalloprotease domain of This study 
   human ADAM10        
ADAM12 Extra Rabbit, polyclonal/ extracellular domain of   This study 
   human ADAM12 
ADAM15 Peptide Rabbit, polyclonal / AA189-208 of human  S. Hart 
   ADAM15 
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ADAM17 (19027) Rabbit, polyclonal / AA807-823 of human   Chemicon, Hofheim 
   ADAM17 
Akt1/2   Rabbit, polyclonal/ AA 345-480 of human Akt1  Santa Cruz, USA 
P-Akt/PKB   Rabbit, polyclonal/ phospho-Akt (Ser-473);  NEB 
   Recognizes p-Akt of human, rabbit and rat origin 
Edg2    Rabbit polyclonal/ AA    Kamya Biomedical, 
   recognizes the cytoplasmic domain of human and  USA 
rat Edg2    
EGFR    Sheep, polyclonal/ part of cytoplasmic domain  UBI, Lake Placid 
of the human EGFR 
EGFR (108.1)  Mouse, monoclonal/ ectodomain of the human  (Daub et al., 1997) 
EGFR 
EGFR Cuba  Mouse monoclonal/ ectodomain of the human Habana, Cuba 
   EGFR, IOR-R3 
ERK2 (C-14)  Rabbit, polyclonal/ peptide at C-terminus of rat  Santa Cruz, USA 
ERK2 
ERK2 (K-23)   Rabbit, polyclonal/ peptide from sub-domain XI  Santa Cruz, USA 
of rat ERK2 
P-ERK   Rabbit, polyclonal; recognizes phospho-p44/p42  NEB, Frankurt/M. 
(Thr-202/ Tyr-204) MAPK 
Gαi/o/t/z (C-20)  Rabbit, polyclonal/ peptide at carboxy terminus of Santa Cruz, USA  
Gαz of rat origin; recognizes mouse, rat and human  
Gαi/o/t/z
Gαi2 (T-19))  Rabbit, polyclonal/ divergent domain of human Santa Cruz, USA 
  Gαi2; recognizes mouse, rat and human Gαi2
Gαq (E-17)  Rabbit, polyclonal/ peptide of AA 13-29 of mouse Santa Cruz, USA 
  Gαq; recognizes mouse, rat and human Gαq
Gα12 (S-20)  Rabbit, polyclonal/ peptide of AA 2-21 of mouse Santa Cruz, USA 
  Gα12; recognizes mouse, rat and human Gα12    
Gα13 (A-20)  Rabbit, polyclonal/ peptide of AA 2-21of mouse Santa Cruz, USA 
  Gαq13; recognizes mouse, rat and human Gα13
Gβ1 (C-16)  Rabbit, polyclonal/ divergent domain of human Santa Cruz, USA 
   Gβ1; recognizes mouse, rat and human Gβ1
Gγ2 (A-16)  Rabbit, polyclonal/ amino terminus of bovine Gγ2; Santa Cruz, USA 
   Broad mammalian reactivity 
GFP  mouse, monoclonal; recognizes the green   G. Gerisch 
  Fluorescent protein (GFP) 
HA    Mouse, monoclonal; recognizes the influenza  Babco, CA, USA 
hemagglutinin epitope (HA)     
SHC    Mouse, monoclonal      Santa Cruz 
SHC    Rabbit, polyclonal/ 220 AA at C-terminus of  (Daub et al., 1997) 
human SHC 
P-Tyr (4G10)   Mouse, monoclonal; recognizes phospho-   UBI, Lake Placid 
(3)-tyrosine residues 
 
For western blot secondary antibodies conjugated with horseradish peroxidase (HRP) were 
utilized. 
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Antibody     Dilution     Origin 
 
Goat anti-mouse    1 : 10,000     Sigma, Karlsruhe 
Goat anti-sheep    1 : 25,000     Dianova, Hamburg 
Goat anti-rabbit    1 : 25,000     BioRad, München 
 
2.1.11 Plasmids and oligonucleotides 
 
2.1.11.1 Primary vectors 
 
Vector   Description      Origin/ Reference 
 
pcDNA1  Mammalian expression vector,   Invitrogen, USA 
SupF gene, ColE1/M13 origin,  
CMV/T7 promoter, SV40 origin   
pcDNA3  Mammalian expression vector, Ampr,  Invitrogen, USA 
CMV promotor, BGH pA,    
high copy number plasmid 
pCEFL  modified pcDNA3, CMV promoter   S. Gutkind 
replaced by EF-1 
pLXSN   Expression vector for retroviral gene  Clontech, Palo Alto, USA 
transfer, Ampr, Neor, origin from pBR322, 
5’-LTR and 3’-LTR from MoMuLV, 
SV40 promotor 
pLXSN-ESK   Modified pLXSN vector with multipe  J. Ruhe 
cloning site from pBluescript 
pRK5    Expression vector, Ampr, CMV   Genentech, 
promoter, SV 40 poly A, high  San Francisco, USA 
copy number plasmid 
pCEP4   Mammalian expression vector, CMV  Invitrogen, USA 
   promoter, SV40 pA, OriP, EBNA-1 gene 
   (complementary strand), Ampr,  
pUC origin, TK promoter, Hygromycinr,  
TK pA       
pCDM8  Mammalian high copy expression Vector, Invitrogen, USA 
   SupF gene, pMBI origin from pBR322,  
M13 origin, CMV/T7 promoter,  
SV40 origin 
pGEX5x-3  Bacterial expression vector for GST-fusion Amersham, USA 
   proteins, pBR322 origin, tac promo ter,  
Ampr,, lac Iq gene, protease recognition  
sites 
pBABEpuro  Expression vector for retroviral gene  C. Marshall 
   transfer, Ampr, Puror, pBS origin,      
   SV40  promoter 
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pRetroSuper  Mammalian expression vector, also  (Brummelkamp et al., 2002)
   suitable for retroviral gene transfer,  
H1-RNA promoter for RNA transcription  
under control of PolIII, PGK promoter,  
Puror, Ampr 
pcdef3   Mammalian expression vector, Ampr,   E. Goetzl 
   Neor, EF1a promoter, BGH pA,  
   SV40 promoter       
pRC/CMV2  CMV/T7 promoter, BGH pA, f1 origin, Invitrogen, USA 
   SV40 promoter, , Ampr, Neor,  
ColE1 origin 
 
2.1.11.2 Constructs 
 
Vector     Description     Reference 
 
pGEX-5x3-ADAM10,MP  cDNA of human ADAM10,  This study 
metalloprotease domain,  
AA 214-455 in pGEX5x-3 
pCEP4-ADAM12E-GST  cDNA of human ADAM12,  This study,  
     extracellular domain, AA 1-708 S. Hart 
     in pCEP4; C-terminal GST tag 
pcDNA3-hADAM10-HA   cDNA of human ADAM10   A. Gschwind 
in pcDNA3; C-terminal HA-tag 
pRetroSuper- ADAM10si  Expression of a RNA oligomer This study  
targeting the 3’ UTR of human  
ADAM10 in pSuper.retro 
 pcDNA1-Gαi2 wt   cDNA of Gαi2 wt in pcDNA1 M. Fauré  
 pcDNA1-Gαi2 Q→L    cDNA of Gαi2 (Q205→L) in  M. Fauré 
pcDNA1 
pcDNA3 –Gα13 wt-HA  cDNA of Gα13 wt in pcDNA3; S. Gutkind 
      C-terminal HA-tag 
pcDNA3- Gα13 Q→L-HA  cDNA of Gα13 (Q226→L) in  S. Gutkind 
     pcDNA3; C-terminal HA-tag 
 pCEFL Gα12 wt   cDNA of Gα12 wt in pcDNA3 S. Gutkind 
 pCEFL Gα12 Q→L   cDNA of Gα12 (Q229→L) in  S. Gutkind 
      pCEFL 
 pCEFL Gαq wt-HA   cDNA of Gαq wt in pCEFL;  S. Gutkind 
      C-terminal HA-tag 
 pCEFL Gαq Q→L-HA  cDNA of Gαq (Q   →L) in  S. Gutkind 
      pCEFL; C-terminal HA-tag 
pcDNA3-Edg2   cDNA of human Edg2 in  This study 
     pcDNA3 
 pRC-CMV2-Edg2   cDNA of  Edg2 in pRC-CMV2 E. Goetzl 
pcDNA3-Edg4   cDNA of human Edg4 in  This study 
     pcDNA3 
 pdef3-Edg4    cDNA of Edg4 in pcdef3  E. Goetzl 
pcDNA3-Edg7   cDNA of human Edg7 in  This study 
     pcDNA3 
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2.1.11.3 Important oligonucleotides  
 
Name   Sequence        
 
Cloning of ADAM10MP into pGEX5x-3 
 
ADAM10MP 3’ GCGCTCGAGTCCTCCGCCAGATCCAACAAAACAGTTG  
ADAM10MP 5’ CGCCTCGAGGCCACCATGAATGGTCCAGAACTTCTGAGG 
 
Cloning of ADAM12E + GST into pCEP4 
 
ADAM12ex1  AGAGATATCGCCACCGCCGGCGACGATGGCAGTG 
ADAM12ex2  AGATCTAGAGGAGGATTGGTTATCTGCTTGCCGGATGG 
 
GST 3’  GCCAGATCTTTACAGATCCGATTTTGGAGGATG 
GST 5’  GCGGATCCTCCCCTATACTAGGTTATTGG 
 
Cloning of ADAM10siRNA into pRetroSuper 
    
AD10(2)a  GATCCCCACTTGGCTCTCAATAAACTTTCAAGAGAAGTTTATT 
GAGAGCCAAGTTTTTTGGAAA 
AD10(2)b  AGCTTTTCCAAAAAACTTGGCTCTCAATAAACTTCTCTTGAAA 
GTTTATTGAGAGCCAAGTGGG 
 
Subcloning of Gα subunits into pLXSN/pBABEpuro 
 
Alphai2forwEcoRI GCGAATTCGCCACCATGGGCTGCACCGTGAGCGC  
Alphai2revEcoRI CGGAATTCTCAGAAGAGGCCACAGTCCTT 
AlphaqforwBamHI GCGGATCCGCCACCATGACTCTGGAGTCCATCATGGC 
AlphaqrevBamHI CGGGATCCTTAGACCAGATTGTACTCCTTCAG 
Alpha13forwBamHI GCGGATCCGCCACCATGGCGGACTTCCTGCCGTCG 
Alpha13revBamHI CGGGATCCTCACTGCAGCATGAGCTGCTT 
 
Cloning of Edg2, 4 and 7 into pcDNA3 
 
Edg2 BamHI 3’ GCGGGATCCGCCACCATGGCTGCCATCTCTACTT   
Edg2 ApaI 5’  GCGGGGCCCCTAAACCACAGAGTGGTCATT  
Edg4 BamHI 3’ GCGGGATCCGCCACCATGGTCATCATGGGCCAGT   
Edg4 ApaI 5’  GCGGGGCCCCTAAAGGGTGGAGTCCATC  
Edg7 BamHI 3’ GCGGGATCCGCCACCATGAATGAGTGTCACTATGACA  
Edg7 ApaI 5’  GCGGGGCCCTTAGGAAGTGCTTTTATTGCAG   
 
RT-PCR primers for Edg2, 4 and 7 and rat actin 
 
hEdg2aRT  TCTTCTGGGCCATTTTCAAC    
hEdg2bRT  TGCCTAAAGGTGGCGCTCAT    
hEdg4aRT  CCTACCTCTTCCTCATGTTC     
hEdg4bRT  TAAAGGGTGGAGTCCATCAG     
hEdg7aRT  GGAATTGCCTCTGCAACATCT     
hEdg7bRT  GAGTAGATGATGGGGTCCA     
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rat-beta-actina  TACAACCTCCTTGCAGCTCC     
rat-beta-actinb GGATCTTCATGAGGTAGTCTGTC    
   
2.1.11.4 siRNA nucleotides 
 
siRNA   Sequence  
      
gl2   CGUACGCGGAAUACUUCGAdTdT 
   
ADAM10   UGAAGAGGGACACUUCCCUdTdT 
GUUGCCUCCUCCUAAACCAdTdT 
 
ADAM15   CUCCAUCUGUUCUCCUGACdTdT 
AUUGCCAGCUGCGCCCGUCdTdT 
 
ADAM17   GUUUGCUUGGCACACCUUdTdT 
GUAAGGCCCAGGAGUGUUdTdT 
 
  
siRNAs (Dharmacon Research, Lafayette, CO, USA) were described earlier (Fischer, 2004). 
 
2.2 Methods in molecular biology 
 
2.2.1  Plasmid preparation for analytical purpose 
 
Small amounts of plasmid DNA were prepared as described previously (Lee and Rasheed, 
1990). 
 
2.2.2 Plasmid preparation in preparative scale 
 
For transfection experiments of mammalian cells DNA of high quality was prepared using 
Qiagen Maxi-Kits (Qiagen, Hilden) according to the manufacturer’s recommendations. 
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2.2.3 Enzymatic manipulation of DNA 
 
2.2.3.1 Digestion of DNA samples with restriction endonucleases 
 
Restriction endonuclease cleavage was accomplished by incubating the enzyme(s) with the 
DNA in appropriate reaction conditions. The amounts of enzyme and DNA, the buffer and 
ionic concentrations, and the temperature and duration of the reaction were adjusted to the 
specific application according to the manufacturer's recommendations. 
 
2.2.3.2 Dephosphorylation of 5'-termini with calf intestine alkaline phosphatase (CIAP) 
 
Dephosphorylation of 5'-termini of vector DNA in order to prevent self-ligation of vector 
termini. CIAP catalyzes the hydrolysis of 5'-phosphate residues from DNA, RNA, and ribo- 
and deoxyribonucleoside triphosphates. The dephosphorylated products possess 5'-hydroxyl 
termini. 
For dephosphorylation 1-20 pmol DNA termini were dissolved in 44 µL deionized water,  
5 µL 10x CIAP buffer (500 mM Tris/HCl pH 8.0, 1 mM EDTA pH 8.5) and 1 µL CIAP (1 
U/µL). The reaction was incubated 30 min at 37° C and stopped by heating at 85° C for  
15 minutes. 
 
2.2.3.3 DNA insert ligation into vector DNA 
 
T4 DNA Ligase catalyzes the formation of a phosphodiester bond between juxtaposed  
5'-phosphate and 3'-hydroxyl termini in duplex DNA. T4 DNA Ligase thereby joins 
doublestranded DNA with cohesive or blunt termini. 
The digested, dephosphorylated and purified vector DNA (200 ng), the foreign DNA insert,  
1 µL 10x T4 DNA Ligase buffer (0.66 M Tris/HCl pH 7.5,  50 mM MgCl2, 50 mM DTT, 10 
mM ATP) and 1 µL T4 DNA Ligase (2 U for sticky ends and 4 U for blunt ends) were added 
to a total volume of 10 µL. The reaction was incubated at 15° C overnight. T4 DNA Ligase 
was inactivated by heating the reaction mixture at 65° C for 10 min. The resulting ligation 
reaction mixture was directly used for bacterial transformation. 
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2.2.4 Agarose gel electrophoresis 
 
Agarose gel electrophoresis is a simple and highly effective method for separating, 
identifying, and purifying 0.5- to 25 kb DNA fragments. 1-2 % horizontal agarose gels with 
1x TAE electrophoresis buffer were used for separation. The voltage was typically set to  
1-10 V/cm gel length. Gels were stained by covering the gel in a dilute solution of ethidium 
bromide (0.5 µg/ml in water) and gently agitating for 30 min and destained by shaking in 
water for an additional 30 min. 
 
2.2.4.1 Isolation of DNA fragments using low melting temperature agarose gels 
 
Following preparative gel electrophoresis using low melting temperature agarose, the gel slice 
containing the band of interest was removed from the gel. This agarose slice was then melted 
and subjected to isolation using the QIAquick Gel Extraction Kit (Qiagen, Hilden). 
 
2.2.5 Introduction of plasmid DNA into E.coli cells 
 
2.2.5.1 Preparation of competent E. coli bacteria 
 
Competent cells were made according to the procedure described before (Chung and Miller, 
1988). For long-term storage competent cells were directly frozen at -70° C. Transformation 
frequency ranged between 106 and 107 colonies/µg DNA. 
 
2.2.5.2 Transformation of competent E. coli bacteria 
 
100 µL competent cells were added to 10 µL ligation mix and 20 µL 5x KCM (500 mM KCl, 
150 mM CaCl2, 250 mM MgCl2) in 70 µL H2O and incubated on ice for 20 min. Upon 
incubation at room temperature for 10 min, 1 ml LB medium was added and incubated for 1 h 
at 37° C with mild shaking to allow expression of the antibiotic resistance gene. 
Transformants were selected on appropriate LB-plates. 
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2.2.6 Enzymatic amplification of DNA by polymerase chain reaction (PCR) 
 
The polymerase chain reaction (PCR) is a rapid procedure for in vitro enzymatic amplification 
of a specific segment of DNA (Mullis and Faloona, 1987). A multitude of applications have 
been developed including direct cloning from cDNA, in vitro mutagenesis and engineering of 
DNA, genetic fingerprinting of forensic samples, assays for the presence of infectious agents 
and analysis of allelic sequence variations. For long and accurate cDNA amplification 
LATaq™ polymerase (TaKaRa) and Pfu DNA polymerase (Fermentas) were used according 
to the manufacturer’s recommendations: 
 
0.5 µL template cDNA 
2.0 µL "sense" oligonucleotide, 10 pmol/µL 
2.0 µL "antisense" oligonucleotide, 10 pmol/µL 
5.0 µL  10x LA PCR buffer II (without MgCl2) 
5.0 µL  25 mM  MgCl2 
8.0 µL  dNTP-Mix, 2.5 mM each 
0.5 µL  LA-Taq™ (5 U/µL) 
 
add to 50 µL H2O 
 
or  0.5 µL template cDNA 
2.0 µL "sense" oligonucleotide, 10 pmol/µL 
2.0 µL "antisense" oligonucleotide, 10 pmol/µL 
5.0 µL  10x Pfu-buffer with  MgSO4
4.0 µL  dNTP-Mix, 2.5 mM each 
0.5 µL  Pfu DNA Polymerase (2.5 U/µl) 
 
add to 50 µL H2O 
 
PCR reactions were performed in an automated thermal cycler („Progene“, Techne). The 
following standard protocol was adjusted to the specific application: 
 
initial denaturation:   3 min    94° C 
amplification 20-35 cycles:   1 min     94° C (denaturation) 
1 min     50-65° C (hybridization) 
1 min respective  
2 min/ kb product   72° C (extension) 
final extension:    7 min     72° C 
 
10 µL from each reaction were electrophoresed on an agarose gel appropriate for the PCR 
product size expected. PCR products were subjected to isolation using the PCR purification 
kit (Qiagen). 
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2.2.7 RT-PCR analysis 
 
Expression of Edg2, 4 and 7 was confirmed by RT-PCR analysis. RNA isolated using RNeasy 
Mini Kit (Qiagen, Hilden) was reverse transcribed using AMV Reverse Transcriptase (Roche, 
Mannheim). 2-10 µg RNA and 1 µl random primer in a volume of 10 µl were incubated for2 
min at 68°C, followed by 10 min RT. After addition of 0.5 µl RNase inhibitor, 4 µl 5x AMV 
RT buffer and 4 µl dNTPs (2.5 mM each) and 1µl AMV RT the volume was adjusted to 20 
µl. The reaction mix was incubated at 42°C for 1h.  
PuReTaq Ready-To-Go PCR Beads (Amersham Biosciences, Piscataway, NJ) and 1µl RT-
PCR products were used for PCR amplification according to the manufacturer’s 
recommendations. PCR products were subjected to electrophoresis on 1.5-2% agarose gels 
and DNA was visualized by ethidium bromide staining. 
 
2.2.8 DNA sequencing 
 
DNA sequencing was performed according to the “Big Dye Terminator Cycle Sequencing 
Protocol” (ABI). The following mix was subjected to a sequencing-PCR run: 
 
0.5 µg    DNA of interest 
10.0 pmol   oligonucleotide 
4.0 µL   Terminator Ready Reaction Mix 
add to 20 µL   H2O 
 
25 cycles:    30 sec    94° C 
15 sec    45-60° C (annealing temperature) 
4 min    60° C 
 
The sequencing products were purified by sodium acetate/ EtOH precipitation, dissolved in  
20 µL template suppression reagent, denatured for 2 min at 90° C and analyzed on a           
310-Genetic Analyzer (ABI Prism). 
 
2.2.9 cDNA array hybridization 
 
Filters spotted with genes of interest (cloned into pBluescript SKII+) were a generous gift 
from A. Roidl. cDNA probes of the cell lines under varying conditions were generated by  
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T. Knyazeva according to standard molecular biology methods. Labeling of 3–5 µL of cDNA 
was performed by P. Knyazev with the Megaprime kit (Amersham) in the presence of  
50 µCi [α-32P]dATP. The prehybridization solution was replaced from filters by the 
hybridization solution containing 5x SSC, 0.5% (v/v) SDS, 100 µg/mL baker’s yeast tRNA 
(Roche), and the labelled cDNA probe (2–5 x 106 cpm/mL) and incubated at 68° C for 16 h. 
Filters were washed under stringent conditions. A phosphorimager system (Fuji BAS 1000; 
Fuji) was used to quantify the hybridization signals. Average values for each slot were 
calculated using the formula: A = (AB - B) x 100/B; [A, final volume; AB, intensity of each 
slot signal (pixel/mm2); B, background (pixel/mm2)]. 
 
2.3 Methods in mammalian cell culture 
 
2.3.1 General cell culture techniques 
 
Cell lines were grown in a humidified 93 % air, 7 % CO2 incubator (Heraeus, B5060 Ek/CO2) 
at 37° C and routinely assayed for mycoplasma contamination using a bisbenzimide staining 
kit (Sigma, Karlsruhe). Before seeding, cells were counted with a Coulter Counter (Coulter 
Electronics). Cells were cultured in the medium recommended by the manufacturer. The 
following cell lines required special media additives: 
 
SCC9   Dulbecco's modified Eagle's medium (DMEM)/ Ham's F12 medium 1:1 
containing 0.5 mM sodium pyruvate, 2 mM L-glutamine, 400 mg/L 
Hydrocortisone and 10 % FCS. 
MCF10A Dulbecco's modified Eagle's medium (DMEM)/ Ham's F12 1:1 containing     
0.5 mM sodium pyruvate, 5 % horse serum, 80 U/L Insulin, 1 mg/ml 
Hydrocortisone, 500 µg/ml Choleratoxine, 100 mg/ml EGF. 
BT20, A498  Eagle's minimum essential medium (MEM) containing 10 % FCS, 1 mM 
sodium pyruvate, 2 mM L-glutamine and  0.1 mM non-essential amino acids. 
BT549  RPMI 1640 containing 10 % FCS, 2 mM L-glutamine and 2.67 U/L Insulin. 
HS578T Dulbecco's modified Eagle medium (DMEM) containing 10 % FCS, 1 mM 
sodium pyruvate, 2 mM L-glutamine and 10µg/ml Insulin. 
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2.3.2 Transfection of cultured cell lines 
 
2.3.2.1 Transfection of cells with calcium phosphate 
 
HEK-293T and EBNA cells in six-well dishes were transfected transiently at about 70% 
confluency with a total of 2 µg DNA by using a modified calcium phosphate precipitation 
method as described previously (Chen and Okayama, 1987). In this protocol, a calcium 
phosphate-DNA complex is formed gradually in the medium during incubation with cells. 
The transfection mix of DNA and CaCl2 in water was prepared as follows: 
 
Dish    6-well    6 cm    10 cm 
Area    10 cm2   21 cm2   57 cm2
Volume of medium  1 ml    2 ml    4 ml 
DNA in H2Obidest  2 µg in 90 µL   5 µg in 180 µL  10 µg in 360 µL 
2.5 M CaCl2   10 µL    20 µL    40 µL 
2 x BBS (pH 6.96)  100 µL   200 µL   400 µL 
Total volume   200 µL   400 µL   800 µL 
 
To initiate the precipitation reaction the indicated volume of 2x BBS was added and mixed by 
vortexing. The reaction was incubated for 10 min at room temperature before being added to 
each well. Plates were placed in a humidified container at 3% CO2 overnight. One day after 
transfection, cells were serum-starved for 24 hours in standard cell culture medium without 
FCS. Transfection efficiency was determined by LacZ staining after transfection of a LacZ-
containing expression plasmid. For transfection of Phoenix cells HBS was used instead of 
BBS. 
 
2.3.2.2 Transfection of COS7 cells with Lipofectamine®  
 
COS7 cells were transiently transfected using Lipofectamine® (Gibco-BRL) essentially as 
described (Daub et al., 1997). For transfections in 6-well dishes, 90 µl of serum-free medium 
containing 10 µL of Lipofectamine and 1.5 µg of total plasmid DNA in 100 µl serum-free 
medium were mixed. After 20 min the transfection mixture was added to 800 µl serum-free 
medium per well.  
After 4 h the transfection mixture was replaced by normal growth medium and 20 h later, 
cells were washed and cultured for a further 24 h in serum-free medium until lysis. 
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2.3.2.3 Transfection of A498 cells with Lipofectamine 2000® 
 
A498 cells were transiently transfected using Lipofectamine 2000® (Gibco-BRL) essentially 
according to the manufacturer's recommendations. For transfections in 6-well dishes, 2 µg of 
total plasmid DNA were diluted into 250 µl of serum-free medium. 5 µl Lipofectamine 2000® 
(Gibco-BRL) were also diluted into 250µl of serum-free medium and allowed to incubate at 
room temperature for 5-10 min. After mixing of DNA and transfection reagent, the mixture 
was added to 2 ml of antibiotic-free, but serum containing medium per well. After 4 h the 
transfection mixture was removed and fresh media containing serum was added. After 20 h, 
cells were washed and cultured for a further 48 h in serum-free medium until lysis. 
 
2.3.2.4 RNA interference 
 
Transfection of pRetroSuper-ADAM10si encoding for siRNA duplexes (Dharmacon 
Research, Lafayette, CO) for targeting endogenous ADAM10 or siRNA dublexes 
(Dharmacon Research, Lafayette, CO) targeting ADAM10, 15 and 17 was carried out using 
Lipofectamine® 2000 (Invitrogen, USA) and 2 µg DNA or 5-10 µg siRNA dublexes, 
respectively, per 6-well plate as previously described (Brummelkamp et al., 2002; Tuschl et 
al., 1999). Transfected A498 cells were serum starved and assayed 3 days after transfection. 
Specific silencing of targeted genes was confirmed by western blot (ADAM10 Kuz/ADAM10 
MP). Alternatively, cells were infected as described below. 
 
2.3.3 Retroviral gene transfer in cell lines 
 
The ecotropic packaging cell line Phoenix (Nolan, Stanford, USA) was transfected with 
pLXSN retroviral expression plasmids (Clontech, Palo Alto, CA) encoding wildtype and 
Q→L mutants of  Gα subunits as well as pRetroSuper-ADAM10si by the calcium phosphate/ 
chloroquine method as described previously (Kinsella and Nolan, 1996). 24 h after 
transfection the viral supernatant was collected and used to infect NIH3T3 and Rat1 as well as 
A498 cells (5x 104 cells/6-well plate). 4 to 12 h later, retroviral supernatant was replaced with 
fresh medium. Selection for stable expression was started 48 h post infection with the 
respective antibiotic.  
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2.4 Protein analytical methods 
 
2.4.1 Lysis of eucaryotic cells  
 
Prior to lysis, cells grown to 80% confluence were treated with inhibitors and agonists as 
indicated in the Figure legends. Cells were washed with cold PBS and then lysed for 10 min 
on ice in Triton X-100 lysis buffer. Lysates were precleared by centrifugation at 13000 rpm 
for 10 min at 4° C. For the solubilisation of Gα subunits RIPA lysis buffer was used. The 
solubilisation of Edg-receptors required CHAPS lysis buffer. 
 
2.4.2 Determination of protein concentration in cell lysates 
 
The „Micro BCA Protein Assay Kit” (Pierce, Sankt Augustin) was used according to the 
manufacturer’s recommendations. For samples containing glycerol the BioRad Protein Assay 
(BioRad Laboratories GMBH, Munich) was used according to the manufacturer's 
recommendations. 
 
2.4.3 Immunprecipitation and Isolation of Glycoproteins 
 
An equal volume of HNTG buffer was added to the precleared cell lysates that have been 
adjusted for equal protein concentration. Proteins of interest were immunoprecipitated using 
the respective antibodies and 30 µL of protein A-Sepharose for 4 h at 4° C. Glycoproteins 
werde isolated using 20 µl of Concanavalin A-Sepharose. Proteins bound to the respective 
Separose were washed three times and subsequently removed from the Sepharose by the 
addition of 35 µl Laemmli and heat denaturation. 
GST-tagged proteins werde immunoprecipitated using Gluthation-Sepharose beads with a 
binding capacity of 8 mg Protein per ml. For preparative quantities one ml of Glutathion-
Sepharose was used and incubated for 12 h overnight. The protein was eluted using 
Glutathion elution buffer. 
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2.4.4 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
SDS-PAGE was conducted as described previously (Sambrook, 1990). The following proteins 
were used as molecular weight standards: 
 
Protein   MW (kD)    Protein   MW (kD) 
Myosin   205.0     Ovalbumin   42.7 
ß-Galactosidase  116.25    Carboanhydrase  29.0 
Phosphorylase b  97.4     Trypsin-Inhibitor  21.5 
BSA    66.2     Lysozym   14.4  
 
2.4.4.1 Detection of low-molecular weight proteins 
 
The detection of low-molecular weight proteins by a Tricine-SDS Gel electrophoresis was 
essentially performed as previously described (Schagger and von Jagow, 1987). This method 
has a good resolution for small protein although utilizing 10 % agarose gels.  
 
2.4.4.2 Colloidal Coomassie staining 
 
Protein samples intended for further analysis by mass spectrometry methods were in-gel 
stained with a Roti®-Blue (Roth, Karlsruhe) colloidal Coomassie staining as recommended by 
the manufacturer. 
   
2.4.5 Transfer of proteins on nitrocellulose membranes 
 
For immunoblot analysis proteins were transferred to nitrocellulose membranes (Gershoni and 
Palade, 1982) for 2 h at 0.8 mA/cm2 using a "Semidry”-Blot device in the presence of 
Transblot-SD buffer. Following transfer proteins were stained with Ponceau S (2 g/l in 2% 
TCA) in order to visualize and mark standard protein bands. The membrane was destained in 
water. 
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2.4.6 Immunoblot detection 
 
After electroblotting the transferred proteins are bound to the surface of the nitrocellulose 
membrane, providing access for reaction with immunodetection reagents. Remaining binding 
sites were blocked by immersing the membrane in 1x NET, 0.25 % gelatine for at least 4 h. 
The membrane was then probed with primary antibody (typically overnight at 4° C). 
Antibodies were diluted 1:500 to 1:2000 in NET, 0.25 % gelatin. The membrane was washed 
3x 20 min in 1x NET, 0.25 % gelatin, incubated for 1 h with secondary antibody and washed 
again as before. Antibody-antigen complexes were identified using horseradish peroxidase 
coupled to the secondary anti-IgG antibody. Luminescent substrates were used to visualize 
peroxidase activity. Signals were detected with X-ray films or a digital camera unit. 
Membranes were stripped of bound antibody by shaking in strip-buffer for 1 h at 50° C. 
Stripped membranes were blocked and reprobed with different primary antibody to confirm 
equal protein loading. 
 
2.5 Generation of polyclonal antibodies 
 
2.5.1 Large scale expression of GST-fusion proteins 
 
Bacteria were transformed with the pGEX-5x3-ADAM10MP. Two or three colonies were 
inoculated into 100 ml LB-media with 50 µg/ml ampicillin and grown overnight at 37° C. 
This culture was diluted into 1 L LB-media containing antibiotic and allowed to grow at 37° 
C to an OD600 of 0.4 to 0.5. The expression of the target gene was then induced by the 
addition of 1 ml 0.2 M IPTG to a final concentration of 0.2 mM. After 4 to 5 hours bacteria 
were harvested and centrifuged at 6000 rpm and the pellet was resuspended in 18 ml ice-cold 
RSP-buffer. Bacteria were lysed by sonication at 70 %, 3 times for 1 min on ice. Triton X-100 
was added to a final concentration of 1%. The mixture was the incubated on ice for 5 min 
followed by centrifugation for 5 min at 10000 g at 4° C. The supernatant was incubated with  
1 ml Glutathione-Sepharose beads o/n at 4° C. The beads were washed three times with ice-
cold PBS and then transferred to a BioRad column (BioRad, Munich). The protein was eluted 
with 10 ml elution buffer. Fractions of 1 ml were collected and tested for the presence of the 
protein by SDS-PAGE analysis. Fractions containing the protein were dialyzed against PBS 
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containing 10 % glycerol and protein concentration was measured using BioRad Protein 
Assay (BioRad Laboratories GmbH, Munich). 
For insoluble proteins the pellet from the last step was resuspended in 10 ml 1.5 %  
N-Lauroysarcosine containing 25 mM Triethanoloamine and 1 mM EDTA and incubated for 
1 h at 4° C. After centrifugation the supernatant was also incubated with 1 ml Glutathione-
Sepharose-beads as described above.  
HEK293-EBNA cells were transfected with pCEP4-ADAM12E-GST using the Calcium-
phosphate method as described. After 48 h cells were selected using 1 µm/ml Hygromycin. 
The supernatant was harvested every 2 days for a period of 3 weeks. After centrifugation at 
maximum speed the supernatant was incubated with 1 ml Glutathione-Sepharose beads 
overnight at 4° C. Then, the beads were washed three times with ice-cold PBS and transferred 
to a BioRad column. Elution and dialysis was performed as indicated above. Addititonally, 
cells were lysed using Triton X-100 lysis buffer and then also incubated with 1 ml 
Glutathione-Sepharose beads overnight at 4° C and purification of the protein was performed 
as previously described. 
 
2.5.2 Immunisation of rabbits 
 
Chinchilla and New Zealand rabbits were immunized with 0.5 mg of protein in a 1:1 emulsion 
with Freund's Adjuvans complete (Sigma, Karlsruhe) to a final volume of 2 ml. At day 0, 2 ml 
of preimmune serum were drawn from the ear vein of the rabbit. Two weeks later, a second 
injection of 0.5 mg protein in a 1:1 emulsion with Freund's Adjuvans incomplete (Sigma, 
Karlsruhe) was performed. After two weeks a first test bleed was drawn from the ear vein and 
checked for antibody production. Four to six weeks after the second injection a third injection 
in Freund' Adjuvans incomplete followed. The rabbit was bleed out 14 days after the last 
injection.  
The serum was kept at room temperature for 1 h and then at 4° C overnight. Afterwards, the 
serum was centrifuged at 2000 rpm for 10 min and the supernatant was collected. A second 
centrifugation step at 9000 rpm for 10 min followed and again the supernatant was removed. 
Both supernatants were combined and sodium azide was added to a final concentration of 
0.02 %. The serum was aliquoted and stored at -20° C. 
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2.6 Biochemical and cell biological assays 
 
2.6.1 Stimulation of cells 
 
Cells were seeded in cell culture dishes of appropriate size and grown overnight to about 80% 
confluence. After serum-starvation for 24 or 48 h cells were treated with inhibitors and 
agonists as indicated in the Figure legends, washed with cold PBS and then lysed for 10 min 
on ice. 
2.6.2 Erk 1/2 and Akt/PKB phosphorylation 
 
For determination of Erk 1/2 and Akt phosphorylation, approximately 20 µg of whole cell 
lysate protein/lane was resolved by SDS-PAGE and immunoblotted using rabbit polyclonal 
phospho-specific Erk/MAPK antibody. Akt phosphorylation was detected by protein 
immunoblotting using rabbit polyclonal anti-phospho-Akt antibody. Quantification of  
Erk 1/2 was performed using the Luminescent Image Analyis System (Fuji). After 
quantification of Erk 1/2 phosphorylation, membranes were stripped of immunoglobulin and 
reprobed using rabbit polyclonal anti-Erk 1/2 or rabbit polyclonal anti-Akt antibody to 
confirm equal protein loading. 
 
2.6.3 Erk/MAPK activity 
 
Endogenous Erk 2 was immunoprecipitated from lysates obtained from six-well dishes using 
0.4 µg of anti-Erk 2 antibody. Precipitates were washed three times with HNTG buffer, and 
washed once with kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 
200 µM sodium orthovanadate). Kinase reactions were performed in 30 µL of kinase buffer 
supplemented with 0.5 mg/ml myelin basic protein, 50 µM ATP and 1 µCi of [γ-32P]ATP for 
10 min at room temperature. Reactions were stopped by addition of 30 µL of Laemmli buffer 
and subjected to gel electrophoresis on 15 % gels. Labelled MBP was quantificated using a 
Phosphoimager (Fuji). 
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2.6.4 Focus formation assay 
 
NIH3T3 and Rat1 cells were infected with different Gα-subunits and their oncogenic variant 
using the packaging cell line Phoenix E (Kinsella and Nolan, 1996). Ras-infected cells were 
utilized as a positive control. The cells were stimulated with 10 µg/ml LPA every other day. 
Cells were cultured for 2-3 weeks until foci were visible and subsequently fixed and stained 
with crystal violet. (0.5 % crystal violet, 20 % methanol).  
 
2.6.5 Proliferation assay 
 
In a 96-well flat bottom plate (Nunc, Naperville, Ill.) approximately 2,000 cells/100 µl of cell 
suspension were seeded. Upon serum-starvation for 24 h cells were incubated with inhibitors 
and growth factors for the indicated times. MTT, a tetrazolium dye (3-[4,5-dimethylthiazol-2-
y1]-2,5-diphenyltetrazolium bromide; thiazolyl blue, Sigma, St. Louis, MO) was added to 
each well to a final concentration of 1 mg/ml MTT. Plates were incubated in the presence of 
MTT for 4 h. Mitochondrial dehydrogenase activity reduces the yellow MTT dye to a purple 
formazan, which is solubilized (DMSO, acidic acid, SDS)  and absorbance was read at  
570 nm on an micro-plate reader. 
A non-toxic alternative to MTT is Alamar Blue™ (Biosource, Camarilla, CA, USA). 
According to the manufacturer's recommendations, 10 µl of Alamar Blue™ are added to each 
well and absorbance at 590 nm can be read out after different times, because the cells are not 
affected. 
 
2.6.6 In vitro wound closure 
 
The assay was performed as previously described (Fishman et al., 2001) with some 
modifications. Confluent monolayers of kidney and breast cancer cells were wounded with a 
uniform scratch, the medium was removed and cells were washed twice with PBS. Medium 
without FCS was added and cells were subjected to 20 min preincubation with DMSO 
(control), 250 nM AG1478, 10 µM batimastat or 10 nM Ki16425 before ligand treatment. 
Cells were permitted to migrate into the area of clearing for 8-24 h. Wound closure was 
monitored by visual examination using a Zeiss microscope. 
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2.6.7 Migration of cancer cells 
 
Cell migration assays of A498 kidney cancer and MDA-MB 231 breast cancer cells were 
performed using Transwells (Sieuwerts et al., 1997). Serum free medium containing LPA as a 
chemoattractant was added to the lower well of a chamber.  1x105 cells in exponential growth 
were harvested and then preincubated with the respective inhibitor for 20 min and added to 
the upper well of the chamber in serum free medium. The chambers were incubated for 6-24 h 
in a humidified 7 % CO2, 37° C incubator. Finally, the cells that have migrated to the lower 
surface of the membrane were stained with crystal violet and counted under the microscope. 
Alternatively, cells migrated to the lower surface were fixed with methanol and stained with 
crystal violet. The stained cells were solubilized in 10 % acetic acid, and the absorbance at 
570 nm was measured in a micro-plate reader.  
 
2.7 Statistical analysis 
 
Student's t-test was used to compare data between two groups. Values are expressed as mean 
± standard deviation (s. d.) of at least triplicate samples. P<0.05 was considered statistically 
significant.
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3 Results 
 
The EGFR signaling pathway is known to be involved in the regulation of various cellular 
processes and is a key player in hyperproliferative diseases such as cancer (Zwick et al., 2001; 
Zwick et al., 1999).  
Furthermore, a novel pathway linking GPCRs to the EGFR signal pathway has been 
discovered involving the shedding of EGF-like ligands by a metalloprotease (Daub et al., 
1996; Prenzel et al., 1999). 
The aim of the study was to elucidate the relevance of the EGFR signal transactivation by 
GPCR agonists in the development and progession of cancer. The focus of the investigation 
was to analyze the pathway activating the metalloprotease by GPCR ligands.  
 
3.1 ADAM-specific antibodies 
 
The development of new tools for the investigation of the EGFR transactivation signal was of 
primary interest. Antibodies specifically blocking the metalloprotease function of ADAM 
proteins can be helpful in the investigation of the role of the metalloprotease in the EGFR 
transactivation pathway and may lead to the design of novel therapeutics. 
The metalloprotease domains of different ADAM proteins were expressed in the mammalian 
cell line HEK293, but it was soon recognized that the metalloprotease domain itself is neither 
correctly processed nor stably secreted. These findings were confirmed by the study of 
Schlondorff et al. who found that the prodomain of ADAM proteins is necessary for correct 
processing and intracellular maturation of ADAM proteins (Schlondorff et al., 2000).  
Therefore, the metalloprotease domain of ADAMs which is not heavily glycosylated was 
bacterially expressed. The complete extracellular fragment of ADAM proteins including the 
prodomain was expressed in the mammalian cell line HEK293EBNA.   
 
3.1.1 ADAM10,MP antibody 
 
The metalloprotease domain of ADAM10 fused to an N-terminal GST-tag was successfully 
expressed in the bacterial expression system DH5α and purified using GSH-Sepharose beads. 
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The beads with the bound protein were then used to immunize a Chinchilla rabbit. The 
resulting antibody serum was tested for its specificity (Figure 9). 
 
 
 
Fig. 9. Specificity test of ADAM10,MP polyclonal serum. Equal amounts of lysate from HEK293 cells 
overexpressing Mock control, Erk2-HA control, ADAM10wt-HA, the mutants ADAM10,E→A-HA and 
ADAM10A→F-HA were immunoblotted (IB) with HA-tag antibody and ADAM10,MP polyclonal serum, 
respectively. 
 
The antibody revealed not to be specific in immunoprecipitation experiments as N-terminal 
sequencing and MALDI-TOF analysis of the respective bands proved (data not shown), but it 
was a useful tool for immunoblot analysis. However, this antibody was not suitable for the 
detection of point mutations in the metalloprotease region of ADAM10 as all mutants are 
equally well recognized. 
 
3.1.2 ADAM12 antibody 
 
The complete extracellular fragment of ADAM12 fused to an N-terminal GST-tag was 
expressed in HEK293EBNA cells. As the secretion of the soluble fragment was insufficient, 
both the secreted protein and the protein from the cell lysate were purified using  
GSH-Sepharose beads and used for immunization of a New Zealand rabbit. Subsequently, the 
serum was tested for its specificity (Figure 10). 
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Fig. 10. Specificity test of ADAM12E polyclonal serum. Equal amounts of lysate from HEK293 cells 
overexpressing ADAM12-HA were submitted to immunoblot (IB) analysis with HA-tag antibody and 
ADAM12E polyclonal serum as indicated. Additionally, immunoprecipitation (IP) with equal amounts of lysates 
was performed using 3 µl HA antibody and the indicated amounts of ADAM12E polyclonal serum and 
subsequently immunoblotted (IB) with HA-tag antibody and ADAM12E polyclonal serum, respectively. 
 
ADAM12E antibody serum was able to detect overexpressed ADAM12 both in immunoblot 
analysis and in immunoprecipitation experiments. In immunoprecipitation analysis, the active 
form of ADAM12 could also be visualized. Futrther experiments demonstrated that 
endogenous expression of ADAM12 can only be demonstrated if the protein level is 
comparably high (data not shown). 
 
3.2 Reconstituted LPA receptor expression in McA-RH7777 cells 
 
LPA is the strongest mitogenic factor present in serum and is believed to be involved in the 
development and progession of different cancer types including breast, ovarian, colon and 
prostate cancer (Fang et al., 2000a; Fishman et al., 2001; Goetzl et al., 1999; Kue et al., 2002; 
Shida et al., 2003). Therefore, it was of utmost interest to study the functions of the  
LPA receptors and their involvement in the transactivation of the EGFR signaling pathway. 
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3.2.1 Stable expression of LPA receptors in McA-RH7777 cells 
 
The McA-RH7777 cell line is known to be deficient of any expression of the LPA receptors 
Edg2, 4 and 7 (Im et al., 2000). Thus, it represents an ideal model system for analyzing 
differential functions of the three LPA receptors of the Edg receptor family. In this study, 
polyclonal cell lines stably expressing the LPA receptors Edg2, 4 and 7 were established. 
Expression of the LPA receptors was determined by RT-PCR (Figure 11). 
 
 
 
Fig. 11. RT-PCR analysis of the polyclonal McA-RH7777 cell lines stably expressing Edg 2, 4 and 7. Equal 
amounts of total RNA isolated from McA-RH7777 cells stably expressing the respective receptor or Mock-
control were subjected to RT-PCR analysis. PCR products were amplified using PuReTaq Ready-to-Go PCR 
beads with the respective primers for 35 cycles. Actin mRNA levels demonstrate equal loading. 
 
While the expression level of Edg2 was comparably high in both polyclonal cell lines (Edg2 
and Edg 2G), only the Egd4 but not the Edg4G cell line expressed the Edg4 gene product. The 
expression of Edg7 was comparably weak. Additionally, Figure 11 clearly illustrates that the  
McA-RH7777 cell line was deficient of Edg2, Edg4 and Edg7 mRNA expression. 
 
3.2.2 Expression profile of different ADAM proteins in McA-RH7777 cells 
 
Previous studies revelaed the involvement of ADAM proteins in EGFR signal transactivation 
in various cell lines (Gschwind et al., 2003; Schafer et al., 2004b). Hence, it was important to 
demonstrate the expression of members of this protein family in McA-RH7777 cells. 
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Fig. 12. Expression of ADAM proteins in McA-RH7777 cells.  Equal amounts of lysates from HEK293 cells 
overexpressing Mock control or the respective ADAM construct as well as lysates from the different polyclonal 
McA-RH7777 cell lines were subjected to immunoblot (IB) analysis and probed with the respective antibody as 
indicated.  
 
As shown in Figure 12, expression of ADAM10 and ADAM17 in McA-RH7777 cells was not 
detected in immunoblot analysis. Expression of ADAM12 and ADAM15 could not be 
verified in McA-RH7777 cell lines. ADAM15 and ADAM12 antibodies were specifically 
raised against human ADAMs but due to sequence homology they were suspected to be cross-
reactive with the respective rat protein. 
 
3.2.3 EGFR transactivation can not be restored in cells stably expressing Edg 2, 
4 or 7 
 
Reconstituted expression of LPA receptors in McA-RH7777 cells leads to functional 
signaling of the LPA receptors (An et al., 1998a; An et al., 1997; Bandoh et al., 1999). In the 
context of this study, one important question was if expression of the LPA receptors was able 
to establish a pathway linking LPA stimulation of the LPA receptors to the activation of the 
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EGFR signaling pathway. Hence, McA-RH7777 cells stably expressing the LPA receptors 
Edg2, 4 or 7 were stimulated with LPA and assayed for EGFR activation. In addition, the 
cells were preincubated with known inhibitors of the TMPS pathway as well as the PI3K 
pathway. 
  
 
 
Fig. 13. EGFR phosphorylation induced by LPA stimulation and its inhibition.  McARH7777 cells stably 
expressing Mock control, Edg2 or Edg2G, Edg4 or Edg7 were starved for 24 h and pretreated with either DMSO 
(20 min) as a control or the following inhibitors: PTX (125 ng/ml, 18h), PP1 (20µM, 20 min), LY294,002  
(100 µM, 20 min), BB94 (10 µM, 20 min), Heparin (100 ng/ml, 20 min), AG1478 (250 nM, 20 min) or the 
EGFR blocking antibody Cuba (20µg/ml, 30 min). Afterwards, cells were stimulated with 10 µM LPA or  
3 ng/ml EGF for 3min. Equal amounts of lysate were immunoprecipitated (IP) with EGFR 108 monoclonal 
antibody and immunoblotted (IB) with anti-phosphotyrosine (PY) antibody. Reprobing with EGFR antibody 
ensured equal loading. 
 
The basal phosphorylation of the EGFR was elevated in the McA-RH7777 cell lines stably 
expressing Edg2 and 4, but LPA stimulation did not lead to an increase in EGFR activation. 
Therefore, no inhibition of the EGFR activation was detectable, either. Blocking PI3K 
functionwith the inhibitor LY294,002, however, resulted in increased EGFR phosphorylation 
suggesting that PI3K activity blocks EGFR activation. 
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3.2.4 Restored Erk phosphorylation upon Stimulation with LPA 
 
It was further analyzed if the restored expression of the LPA receptors was able to mediate 
signaling to known downstream targets of the LPA receptors. Among them, the MAPK 
pathway is of primary interest since it activates DNA synthesis and induces cell proliferation 
(Contos et al., 2000). The influence of LPA stimulation on the activation state of the MAPK 
Erk 1/2 was determined by immunoblot analysis (Figure 14).  
 
 
 
Fig. 14. Erk 1/2 phosphorylation induced by LPA stimulation and its inhibition. McARH7777 cells stably 
expressing Mock control, Edg2 or Edg2G, Edg4 or Edg7 were starved for 24 h and pretreated with either DMSO 
(20 min) as a control or the following inhibitors: PTX (125 ng/ml, 18h), PP1 (20µM, 20 min), LY294,002  
(100 µM, 20 min), BB94 (10 µM, 20 min), Heparin (100 ng/ml, 20 min), AG1478 (250 nM, 20 min) or the 
EGFR blocking antibody Cuba (20µg/ml, 30 min). Subsequently, cells were stimulated with 10 µM LPA or  
3 ng/ml EGF for 7 min. Equal amounts of total lysate were immunoblotted (IB) with activation state specific Erk 
antibody followed by reprobing with Erk 1/2 antibody to ensure equal loading. 
 
In Edg2 overexpressing McA-RH7777 cells, LPA stimulation strongly activated Erk 1/2. This 
effect showed to be weaker in Edg4 and Edg7 polyclonal cells, but expression of these 
receptors was comparatively low with respect to the Edg2 overexpressing McA-RH7777 cell 
lines.  
The activation of Erk 1/2 was sensitive to treatment by Pertussis toxin (PTX) which 
specifically inhibits Gαi/o subunits, confirming previous studies that demonstrate LPA 
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mediated signaling to be typically coupled to Gαi/o subunits (Takuwa et al., 2002). Neither the 
src kinase inhibitor PP1 nor the PI3K inhibitor LY294,002 affected the LPA induced Erk 1/2 
activation proving that both kinases were not involved in the activation of Erk 1/2 in this 
cellular context. Interestingly, the metalloprotease inhibitor Batimastat (BB94) and the EGFR 
inhibitor AG1478 as well as the HB-EGF and Pro-Amphiregulin inhibitor Heparin lead to 
abrogation of the LPA induced Erk 1/2 activation, suggesting the involvement of a TMPS 
pathway in activation of the MAPK Erk 1/2, although activation of the EFGR itself could not 
be demonstrated (Figure 13). Inhibition of the EGFR with the blocking antibody Cuba did 
also not influence EGFR phosphorylation, which could have proven the direct involvement of 
the EGFr binding domain. This antibody, however, was specifically designed against the 
human EGFR and might not be functional for rat EGFR.  
 
3.2.5 Akt activation upon stimulation with LPA 
 
In order to analyze whether a separate pathway bypassing the EGFR was activated upon LPA 
stimulation, the activation of the protein kinase PKB/Akt upon stimulation with LPA was 
examined (Figure 15). 
 
 
 
Fig. 15. Akt-activation induced by LPA stimulation and its inhibition. McARH7777 cells stably expressing 
Mock control, Edg2 or Edg2G, Edg4 or Edg7 were starved for 24 h and pretreated with either DMSO (20 min) 
as a control or the following inhibitors: PTX (100 ng/ml, 18h), PP1 (20µM, 20 min), LY294002 (100 µM, 20 
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min), BB94 (10 µM, 20 min), Heparin (100 ng/ml, 20 min), AG1478 (250 nM, 20 min) or the EGFR blocking 
antibody Cuba (20µg/ml, 30 min). Afterwards, cells were stimulated with 10µM LPA or 5ng/ml EGF as a 
control for 7 min. Equal amounts of total lysate were immunoblotted (IB) with activation state specific Akt 
antibody followed by reprobing with an Akt antibody to ensure equal loading.  
 
The basal level of active Akt 1/2 was slightly enhanced, but no specific Akt activation due to 
stimulation with LPA was detected. 
Summarizing the results obtained in McA-RH7777 cells, the expression of LPA receptors, 
especially of Edg2, lead to LPA mediated activation of the MAPK pathway by an Akt 1/2, src 
kinase family and PI3K independendent. However, activation of Erk 1/2 was metalloprotease 
and EGF-like ligand dependent. Additionally, blocking EGFR function with the specific 
inhibtor AG1478 abrogated Erk 1/2 activation suggesting the involvement of the TMPS 
pathway, although the activation of the EGFR itself could not be demonstrated. 
 
3.3 EGFR transactivation in A498 
 
Kidney cancer is one of the most frequent tumors of the urogenital tract. Until today, the most 
effective treatment remains the complete removal of the affected organ (Vogelzang and 
Stadler, 1998). Hence, there is a strong need to identify novel intervention targets for 
prevention and treatment of these tumors. 
Both LPA and Thrombin stimulation have been demonstrated to induce EGFR signal 
transactivation in the kidney carcinoma cell line A498 (Figure 16, (Hart, 2004; Schafer et al., 
2004a). While the EFGR transactivation induced by LPA is mediated predominantly by 
ADAM17, Thrombin induced EGFR transactivation is known to be exclusively mediated by 
ADAM10 (Hart, 2004; Schafer et al., 2004a).  
Therefore, this cell line was selected to study the combined action of two different stimuli as 
well as the specific influence of the metalloprotease ADAM10 on the EGFR signal 
transactivation pathway. 
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Fig. 16. EGFR transactivation induced by LPA and Thrombin stimulation. A498 cells were starved for 48 h 
and subsequently stimulated with 10 µM LPA, 2 U/ml Thrombin or 3 ng/ml EGF for 3 min. Equal amounts of 
lysates were immunoprecipitated with EGFR108 antibody and immunoblotted with phosphotyrosine specific 
antibody. Subsequent reprobing with EGFR antibody verified equal loading. 
 
3.3.1 LPA and Thombin induced EGFR transactivation in A498  
 
Further analysis of the two TMPS pathways activated by LPA and Thrombin demonstrated 
that the two stimuli utilize different pathway which converge at the EGFR. 
LPA as well as Thrombin mediated EGFR transactivation was abrogated with BB94, a broad 
spectrum metalloprotease inhibitor, as well as the EGFR inhibitor AG1478 (Figures 17 and 
18). In A498 cells, the LPA receptor involved in LPA mediated signaling did not couple to 
Gαi/o subunits, because the Gαi/o specific inhibitor Pertussis toxin (PTX) did not inhibit the 
EGFR signal transactivation by LPA. 
 
 
 
Fig. 17. Inhibition of LPA induced EGFR transactivation.  A498 cells were starved for 48 h and preincubated 
with BB94 (5µM, 20 min), AG1478 (250 nM, 20 min), PP2 (20 µM, 20min) or PTX (125 ng/ml, 18 h). 
Subsequently, cells were stimulated with 10 µM LPA or 3 ng/ml EGF for 3 min. Equal amounts of lysated were 
immunoprecipitated with EGFR108 antibody and immunoblotted with phosphotyrosine specific antibody. 
Subsequent reprobing with EGFR antibody verified equal loading. Equal amounts of the same lysate were 
immunoblotted with activation state specific antibodies against Erk 1/2 and subsequently reprobed with Erk 
antibody to ensure equal loading. 
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Additionally, the src kinase inhibitor PP2 was able to reduce the LPA and EGF induced 
EGFR activation by approximately 50 % implying a role for src kinase in the TMPS pathway 
upstream of the EGFR (Figure 17). 
Diphtheria toxin mutant Crm and Heparin, inhibitors of the EGF-like ligand HB-EGF and 
pro-Amphiregulin, did not inhibit Thrombin mediated EGFR signal transactivation (Figure 
18). Therefore, neither pro-Amphiregulin nor HB-EGF were involved in this pathway. Since 
it has been demonstrated that LPA mediated GPCR-EGFR crosstalk involves HB-EGF (Hart, 
2004; Schafer et al., 2004a), the two stimuli activated different metalloproteases and induced 
the shedding of different EGF-like ligands. 
 
 
 
Fig. 18. Inhibition of Thrombin induced EGFR transactivation. A498 cells were starved for 48 h and 
preincubated with Diphtheria toxin mutant Crm (10 µg/ml, 20 min), Heparin (100 ng/ml, 20min) or BB94 (5µM, 
20 min). Subsequently, cells were stimulated with 2 U/ml Thrombin or 3 ng/ml EGF for 3 min. Equal amounts 
of lysates were immunoprecipitated (IP) with EGFR108 antibody and immunoblotted (IB) with PY specific 
antibody. Subsequent reprobing with EGFR antibody verified equal loading. Equal amounts of the same lysate 
were immunoblotted with activation state specific antibodies against Erk 1/2 and subsequently reprobed with Erk 
antibody to ensure equal loading. 
 
3.3.2 Effects of double stimulation of EGFR transactivation in A498 cells  
 
Obviously, two essentially independent pathways resulting in EGFR Phosphorylation were 
activated in A498 cells. Hence, combined stimulation with the two different stimuli LPA and 
Thrombin was suggested to proportionally increase the EGFR transactivation signal. 
Figure 19 demonstrates that LPA induced EGFR signal transactivation was Gαi/o independent, 
but HB-EGF dependent, while Thrombin induced TMPS pathway was Gαi/o dependent, but  
HB-EGF independent as inhibition with PTX, Heparin and Diphtheria toxin mutant Crm 
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proved. Therefore, both pathways only converged at the EGFR. Hence, the EGFR surface 
expression might be the only limiting factor in double stimulation of EGFR signal 
transactivation, but the signal intensity was proportionally increased when both stimuli were 
applied at once, verifiying that the amount of EGFR on the cell surface was not a limiting 
factor. 
 
 
 
Fig. 19. Double stimulation of EGFR transactivation by LPA and Thrombin stimulation. A498 cells were 
starved for 48 h and preincubated with PTX (125 ng/ml, 18 h or 20 min, respectively), Crm (10 µg/ml, 20 min), 
or Heparin (100 ng/ml, 20min). Subsequently, cells were stimulated with 10 µM LPA, 2 U/ml Thrombin, a 
combination of both or 3 ng/ml EGF for 3 min. Equal amounts of lysates were immunoprecipitated (IP) with 
EGFR 108 antibody and immunoblotted (IB) with phosphotyrosine (PY) specific antibody. Subsequent 
reprobing with EGFR antibody verified equal loading.  
 
3.3.3 The effect of ADAM10,MP polyclonal antibody on Thrombin induced 
EGFR transactivation in A498 cells  
 
It is known that Thrombin induced EGFR signal transactivation is mediated exclusively by 
ADAM10, but the role of the metalloprotease activity of ADAM10 in the shedding of EGF-
like ligands had to be further analyzed. Thus, it was studied whether the polyclonal antibody 
serum ADAM10,MP, binding to the metalloprotease domain of ADAM10, inhibited the 
Thrombin induced EGFR activation. 
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Fig. 20. Blocking EGFR transactivation by preincubation with ADAM10MP polyclonal serum. A498 cells 
were starved for 48h and then preincubated with the indicated amounts of ADAM10,MP polyclonal serum. 
Afterwards, cells were stimulated with 3 ng/ml EGF and 2 U/ml Thrombin (A) or 10 µM LPA (B) for 3 min. 
Equal amounts of lysates were immunoprecipitated (IP) with monoclonal EGFR 108 antibody and submitted to 
immunoblot  (IB) analysis with Py specific antibodies. Sebsequent reprobing with EGFR antibody ensured equal 
loading.  Additionally, equal amounts of total lysates were immunoblotted with p-Erk antibody and reprobed 
with Erk antibody to verify equal loading.  
 
Figure 20 demonstrates that the preincubation of A498 cells with ADAM10,MP polyclonal 
serum lead to abrogation of the ADAM10 mediated EGFR signal transactivation induced by 
Thrombin stimulation, but it did not abrogate the activation of the downstream mediator  
Erk 1/2. In addition, the preimmune serum used as a control also diminished EGFR activation, 
proving that this inhibition was an unspecific effect of the serum. The LPA induced EGFR 
transactivation was also inhibited by ADAM10,MP and preimmune serum revealing that this 
inhibition was not a specific property of ADAM10,MP antibodies. 
 
3.3.4 Transactivation is reduced by transient transfection of ADAM10 Si-RNA  
 
A recently discovered method to confirm the involvement of ADAM10 in the Thrombin 
mediated EGFR transactivation in A498 cells is the downregulation of ADAM10 expression 
by small interfering RNAs (siRNAs) (Brummelkamp et al., 2002). Hence, a retroviral 
construct expressing siRNAs against the 3'UTR of ADAM10 was designed and tested in 
transient expression in A498 cells (Figure 21). Targeting a region outside the coding sequence 
of ADAM10 allowed ectopic expression of different ADAM10 constructs. 
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Fig. 21. The expression of ADAM10 is reduced by expression of ADAM10siRNAs. A498 cells were 
transfected with pRetroSuper-ADAM10siRNA. 48 h post-transfection cells were lysed and equal amounts of 
lysate were immunoblotted with ADAM10 antibody. 
 
The expression of ADAM10 in the transfected A498 cells was strongly reduced.  
Subsequently, the effect of ADAM10siRNA on the Thrombin induced EGFR signal 
transactivation was evaluated in order to confirm previous results with synthetic siRNAs 
(Hart, 2004). As shown in Figure 22, the reduction of ADAM10 expression by the expression 
of the pRetroSuper-ADAM10siRNA construct lead to abrogation of the Thrombin induced 
EGFR signal as well as inactivation of the downstream target Erk 1/2.  
 
 
 
Fig. 22. Expression of ADAM10siRNA leads to abrogation of EGFR signal transactivation. A498 cells were 
transfected with pRetroSuper-ADAM10siRNA. Transfected cells were starved for 48 h and then stimulated with 
2 U/ml Thrombin or 3 ng/ml EGF for 3 min. Equal amounts of lysates were immunoprecipitated (IP) with EGFR 
108 antibody and immunoblotted (IB) with phosphotyrosine (PY) specific antibody. Subsequent reprobing with 
EGFR antibody verified equal loading. Equal amounts of the same lysate were immunoblotted (IB) with 
activation state specific antibodies against Erk 1/2 and subsequently reprobed with Erk antibody to ensure equal 
loading. 
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3.3.5 Generation of stably expressing ADAM10siRNA A498 cells 
 
In order to study the influence of different mutants of ADAM10 lacking either the 
metalloprotease domain or the cytoplasmic tail on the EGFR signal transactivation,  
A498 cells were infected either with the pRetroSuper-ADAM10siRNA construct or control 
vector and selected for stable expression with 1 µg/ml Puromycin. After two weeks, colonies 
were picked and monoclonal cell lines were established. These cell lines were tested for the 
expression of ADAM10. Most of the monoclonal cell lines expressing ADAM10 siRNAs 
exhibited a significantly reduced level of ADAM10 expression (Figure 23).  
 
 
 
Fig. 23. The expression levels of ADAM 10 and ADAM17 in A498 cells stably expressing pRetroSuper-
ADAM10siRNA.  A498 cells were infected three times every four hours with retroviral supernatant from 
PhoenixA cells transfected with pRetroSuper-ADAM10siRNA. 24 h post-infection, cells were split and selected 
for expression of ADAM10siRNA with 1µg/ml Puromycin.  Two weeks later, single cell colonies were picked. 
Equal amounts of lysate from the monoclonal cell lines were purified using ConcanavalinA-Spepharose and 
immunoblotted (IB) with ADAM 10 and ADAM17 antibodies, respectively. 
 
However, the downregulation of ADAM10 was not specific as the expression of ADAM17 
was deregulated in a similar fashion (Figure 23). Therefore, these cell lines could not be used 
for studying the specific influence of ADAM10 downregulation.   
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3.3.6 Ki16425 inhibits LPA induced EGFR transactivation and in vitro wound 
closure in A498 cells 
 
Recently, a functional antagonist for the LPA receptors, Ki16425, with a preference for the 
Edg 2 and Edg7 receptor was discovered. Short term action of LPA such as Ca2+-influx and 
cAMP production, but also long term action including migration and DNA synthesis could be 
abrogated by Ki16425 (Ohta et al., 2003; Yamada et al., 2004) 
Preincubation of A498 cells with the LPA receptor antagonist Ki16425 completely abrogated 
LPA induced EGFR signal transactivation (Figure 24). 
 
 
 
Fig. 24. LPA receptor inhibitor Ki16425 abrogates Thrombin induced EGFR signal transactivation in 
A498 cells.  A498 cells were starved for 48 h. Cells were preincubated with DMSO as control or 10 nM Ki16425 
for 20 min. Subsequently, the cells were stimulated with 10 µM LPA for 3 min. Equal amounts of lysate were 
immunoprecipitates with EGFR 108 antibody and immunoblotted (IB) with phosphotyrosine (PY) specific 
antibody. Subsequent reprobing with EGFR antibody verified equal loading. 
 
For the first time, it was unambiguously demonstrated that the G protein coupled receptor was 
directly involved in EGFR signal transactivation. Thus, the LPA mediated transactivation was 
not independent the LPA receptors in A498 cells, but critically relied on the function of the 
LPA receptors. 
LPA induces in vitro wound closure and migration in A498 cells (Schafer, 2004). In addition, 
this study analyzed the direct involvement of the LPA receptors in the LPA mediated wound 
closure and chemotaxis in A498 cells. For this purpose, A498 cells were grown to confluency 
and starved for 48 h. After applying a uniform scratch, cells were preincubated with  
LPA receptor inhibitor Ki16425 or inhibitors of the EGFR transactivation pathway and 
subsequently stimulated with LPA. The cells were allowed to migrate into the wound for 14 h.  
While LPA induced complete wound closure within 14 h, Thrombin stimulation did not lead 
to wound closure in A498 cells. Inhibition with the LPA receptor inhibitor Ki16425 
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completely abrogated LPA induced wound closure, while the inhibitors of the TMPS pathway 
only lead to a reduction in wound closure. Therefore, Ki16425 is the more potent inhibitor of 
LPA induced wound closure, suggesting that the LPA receptors additionally activate a second 
pathway evoking wound closure (Figure 25). LPA was even a more potent stimulus than 
serum for wound closure and chemotaxis (Figure 25).  
 
 
 
Fig. 25. The influence of Ki16425, BB94 and AG1478 on the LPA induced wound closure in A498 cells. 
A498 cells were grown to confluency and starved for 48 h. A uniform scratch was applied using a pipette tip. 
Subsequently, cells were preincubated with 100 nM Ki16425, 5 µM BB94, 250 nM AG1478 or DMSO as a 
control for 20 min and then stimulated with LPA (10 µM), EGF (3 ng/ml) or serum (10 %). Cells were allowed 
to migrate into the wound for 14 h. 
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3.4 EGFR signal transactivation by LPA in breast cancer cells 
 
Breast cancer belongs to the most frequent tumor types in women. The overexpression of 
HER2 which is the preferred binding partner for the EGFR is a marker for the aggressiveness 
of breast cancer tumors. (Pegram et al., 1998; Slamon and Clark, 1988; Slamon et al., 1987; 
Slamon et al., 1989).  In some carcinomas of the breast, overexpression of the EGFR was 
additionally detected (Nicholson et al., 1991). LPA is a potent mitogenic stimulus and has 
been previously implicated in the proliferation and migration of human breast cancer (Goetzl 
et al., 1999; Sliva et al., 2000) 
Therefore, it was of great interest whether transactivation of the EGFR signal by the GPCR 
ligand LPA leads to the aggressive behavior of breast cancer.  
 
3.4.1 Expression of LPA receptors, ADAM proteins and EGF-like ligands in 
breast cell lines  
 
Analysis by cDNA arrays detected an upregulated expression of the LPA receptors in various 
breast cancer cells.  
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Fig. 26. Relative expression of LPA receptors in various breast cell lines as detected by cDNA array 
analysis. On the left are two normal breast cell lines HBL 100 and MCF10A followed by different breast cancer 
cell lines.  
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The normal breast epithelial cell line MCF10A was chosen as control cell line. None of the 
normal breast cell lines exhibited high expression of LPA receptors. The weakly invasive 
adenocarcinoma cell line BT20 expressed all LPA receptors at a low level and served as an 
additional control. On the contrary, the invasive carcinoma cell lines MDA-MB 231, HS578T 
and the invasive ductal carcinoma cell line BT549 highly expressed Edg2, but Edg4 and Edg7 
transcripts were hardly detectable. Therefore, these three cell lines were suitable systems to 
study the influence of a single LPA receptor, namely Edg2 (Figure 26). 
Expression of the gene products of different ADAM proteins were also demonstrated in 
cDNA array analysis (Figure 27). 
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Fig. 27. Expression levels of ADAM proteins in the selected cell lines. Depicted are the relative mRNA 
expression levels of ADAM10, 12, 15 and 17 in selected breast cell lines.  
 
ADAM10 and ADAM17 expression was also detected in immunoblot analysis of the selected 
cell lines. Except for HS578T, all cells strongly expressed ADAM10. ADAM17 was 
expressed by all cell lines to a similar extent (Figure 28). 
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Fig. 28. Detection of ADAM10 and 17 in immunoblot analysis. Equal amounts of lysate from 24 h starved 
cella and cell in normal growth were immunoblotted (IB) with ADAM10 and ADAM17 antibody, respectively. 
 
The expression of EGF-like ligands and the EGFR receptor itself revealed an exceptionally 
high expression of the EGFR in the BT20 cell line and high levels of Amphiregulin in 
MCF10A and MDA-MD 231 cells. BT 20 expressed only low levels of all EGF-like ligands  
(Figure 29). 
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Fig. 29. Expression levels of the EGFR and its ligands in the selected breast cell lines as detected by cDNA 
array analysis. Depicted are relative mRNA expression levels of the EGFR, Amphiregulin, Betacellulin, HB-
EGF and EGF in the indicated breast cell lines.  
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3.4.2 Transactivation of breast cell lines by LPA 
 
The ability to induce EGFR signal transactivation by LPA stimulation was examined in the 
selected cell lines (Figure 30). In addition, the possibility to inhibit basal EGFR and Erk 1/2 
activity with the known inhibitors of the TMPS pathway, Batimastat and AG1478, was 
investigated.  
LPA activated the TMPS pathway both in the normal and the highly invasive breast cancer 
cell lines BT549 and MDA-MB 231. In BT20, the EGFR exhibited high basal 
phosphorylation and no additional induction upon stimulation with LPA was observed. The 
basal EGFR phosphorylation was not blocked by inhibition with Batimastat. On the contrary, 
the EGFR signal transactivation by LPA in MCF10A, BT549 and MDA-MB 231 cells as well 
as the EGFR phosphorylation in normal cells was abrogated by inhibition with Batimastat 
(Figure 30). 
 
 
 
Fig. 30. LPA induces EGFR signal transactivation in MCF10A, BT549 and MDA-MB 231, but not in 
BT20 cells. Cells were starved for 24 h and after preincubation with DMSO as control, 5 µM BB94 or 250 nM 
AG1478 for 20 min and stimulated with 10 µM LPA or 3 ng/ml EGF for 3 min. Additionally, cells in normal 
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growth were incubated with 5 µM BB94 or 250 nM AG1478 for 20 min. Equal amounts of lysates were 
immunoprecipitated (IP) with EGFR 108 antibody and immunoblotted (IB) with phosphotyrosine (PY) specific 
antibody. Subsequent reprobing with EGFR antibody verified equal loading. Equal amounts of the same lysates 
were immunoblotted (IB) with activation state specific antibodies against Erk 1/2 and subsequently reprobed 
with Erk antibody to ensure equal loading. 
 
 
3.4.3 Array data of breast cancer cells  
 
In order to identify crucial players in the transactivation pathway and to further characterize 
these breast cell lines, cDNA array analysis was conducted with the selected breast cell lines 
after serum deprivation and stimulation with LPA as well as cells in normal growth inhibited 
with the broad spectrum metalloprotease inhibitor BB94 for 6 h. 
Dr. Pjotr Knyazev, visiting Professor in the Department of Molecular Biology at the MPIB, 
had previously shown by cDNA array analysis that the LPA receptor Edg2 is overexpressed 
in a large variety of breast cancer cell lines and appeared to be coregulated with several 
metalloproteases. The data obtained from Dr. Knyazevs cDNA array experiments provided 
evidence for a connection of Edg2 with the invasive potential of breast cancer cells and the 
EGFR signal transactivation mechanism, because the LPA receptor Edg2 was observed to be 
coregulated with metalloproteases which are known to be involved in the TMPS pathway in 
breast cancer cells as shown in Figure 31. Edg2 was observed to be in one closely related 
cluster of genes with similar regulation of expression as the metalloproteases ADAM12 and 
MMP14, the metalloprotease inhibitors TIMP1, 2 and 3 and the EGF-like ligand HB-EGF 
(Knyazev, unpublished results).   
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Fig. 31. cDNA array analysis: Cluster I of genes with similarly regulated genes.  MCF10A, BT20, HS578T, 
BT549 and MDA-MB 231 cells were either starved for 24 h and simulated with 10 µM LPAor 3 ng/ml EGF for 
6 h or grown for 24 h and inhibited with 10 µM BB94, control cells were treated with DMSO for 6 h. cDNA 
from these cells was prepared, labeled with α[33P]dATP and hybridized on array filters as described. Data 
obtained from these filters was normalized and subjected to Cluster analysis. Genes depicted in red were highly 
expressed while genes shown in green exhibited an extremely low expression. The correlation factor of this 
cluster was 0.72. 
 
In the highly invasive cell lines HS578T, BT549 and MDA-M 231 these genes were highly 
expressed, while the weakly invasive cell line BT20 exhibited lower expression of these 
genes. The normal breast cell lines exhibited an intermediate expression pattern.  
 
3.4.3.1 The EGFR clusters with HER2 
 
The EGFR itself did not cluster with the other components of the TMPS pathway. Instead, it 
was detected in a separate cluster together with HER2 as shown in Figure 32.  
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Fig. 32. cDNA array analysis: Cluster II of genes with similarly regulated genes.  MCF10A, BT20, HS578T, 
BT549 and MDA-MB 231 cells were either starved for 24 h and simulated with 10 µM LPA or 3 ng/ml EGF for 
6 h or grown for 24 h and inhibited with 10 µM BB94, control cells were treated with DMSO for 6 h. cDNA 
from these cells was prepared, labeled with α[33P]dATP and hybridized on array filters as described. Data 
obtained from these filters was normalized and subjected to Cluster analysis. Genes depicted in red were highly 
expressed while genes shown in green exhibited an extremely low expression. The correlation factor of this 
cluster was 0.79. 
 
While the expression of the EGFR and HER2 was normal to low in the normal breast 
epithelial cell line MCF10A and the highly invasive cell lines HS578T, BT549 and  
MDA-MB 231, the weakly invasive cell line BT20 revealed an exceptionally high expression 
of the EFGR and HER2, which explained the high basal activity of the EGFR. From these 
results, it was concluded that the overall expression pattern correlated with the transactivation 
behavior of the breast cells. LPA was able to induce EGFR signal transactivation in BT549, 
MDA-MB 231 and MCF10A cells with with a low basal EGFR expression and high 
expression of other components of the TMPS pathway, whereas in BT20 cells with an inverse 
gene expression pattern LPA did not induce GPCR-EGFR crosstalk. 
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3.4.3.2 The influence of LPA stimulation and BB94 inhibition on the gene expression 
pattern 
 
The stimulation of starved breast cancer cells as well as inhibition of breast cancer cells in 
normal growth with the broad spectrum metalloprotease inhibitor Batimastat for 6 hours did 
not lead to changes in the gene expression pattern of more than 4 fold as determined in dot 
blot analysis (data not shown) which was the cut-off limit for significant up- or 
downregulation in the studied system. Further analysis with longer stimulation and inhibition 
might reveal more significant changes in the gene expression after LPA stimulation or 
metalloprotease inhibition. 
 
3.4.4 Blocking LPA induced transactivation in breast cells with Ki16425 
 
The discovery of a fairly specific inhibitor for the Edg receptors (Ohta et al., 2003; Yamada et 
al., 2004) allowed to study the direct involvement of the LPA receptors in the EGFR signal 
transactivation.  
The inhibitor Ki16425 strongly decreased LPA induced EGFR signal transactivation in 
MCF10A and MDA-MD231 cells (Figure 33), again clearly demonstrating that the  
LPA receptor Edg2 is directly involved in the EGFR transactivation pathway. Interestingly, 
lower concentrations (10 nM) of the inhibitor yielded stronger inhibition in short term 
experiments. As Sphingosine-1-phosphate also binds to Edg2, the Sphingosine-1-phosphate 
induced transactivation of the EGFR signal was also diminished by preincubation with 
Ki16425. However, other families of GPCRs such as the Thrombin receptor were not 
inhibited by the LPA receptor antagonist Ki16425 proving the specificity of this inhibitor 
(Figure 33). 
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Fig. 33. Low concentrations of Ki16425 can abrogate LPA induced EGFR signal transactivation in breast 
cells. MDA-MB 231 (A) and MCF10A cells (B) were starved for 24 h and after 20 min preincubation with 
Ki16425 (10 and 100 nM as indicated) stimulated with 10 µM LPA, 10 µM Sphingosine-1-phosphate, 2 U/ml 
Thrombin or 3 ng/ml EGF for 3 min. Equal amounts of lysate were immunoprecipitated (IP) with EGFR 108 
antibody and immunoblotted (IB) with PY-specific antibody followed by reprobing with EGFR antibody to 
verify equal loading. 
 
3.4.5 LPA induced wound closure in breast cancer cells 
 
LPA or EGF stimulation did not induce wound closure in the normal breast epithelial cell line 
MCF10A (data not shown), while LPA induces complete wound healing within 12-14 hours 
both in BT549 and MDA-MB 231 cell lines (Figures 34 and 35).  
Contrarywise, EGF as well as Thrombin had hardly any effect on the wound healing behavior. 
The wound healing was completely abrogated by inhibition with LPA receptor inhibitor 
Ki16425 (Figures 34 and 35). Inhibitors of TMPS pathway BB94 as well as AG1478 could in 
comparison to Ki16425 only reduce wound healing (Figure 36). Thus, it had to be concluded 
that a second pathway leading to wound closure is activated by the LPA receptor Edg2. These 
results clearly show that wound closure is only partly mediated by the transactivation pathway 
in BT549 cells. 
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Fig. 34. Ki16425 abrogates LPA induced wound closure in BT549 cells. BT549 cells were grown to 
confluency and starved for 24 h. A uniform scratch was applied using a pipette tip. Subsequently, cells were 
preincubated with 100 nM Ki16425, 5 µM BB94, 250 nM AG1478 or DMSO as a control for 20 min and then 
stimulated with LPA (10 µM), EGF (3 ng/ml) or serum (10 %). Cells were allowed to migrate into the wound for 
14 h. 
 
 
 
Fig. 35. Ki16425 inhibits LPA induced wound closure in MDA-MB 231 cells. MDA-MB 231 cells were 
grown to confluency and starved for 24 h. A uniform scratch was applied using a pipette tip. Subsequently, cells 
were preincubated with 100 nM Ki16425 or DMSO as a control for 20 min and then stimulated with LPA (10 
µM) or EGF (3 ng/ml) or serum (10 %). Cells were allowed to migrate into the wound for 12 h. 
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Fig. 36. The influence of Ki16425, BB94 and AG1478 on the LPA mediated wound closure in BT549 cells. 
BT549 cells were grown to confluency and starved for 24 h. A uniform scratch was applied using a pipette tip. 
Subsequently, cells were preincubated with 100 nM Ki16425, 5 µM BB94, 250 nM AG1478 or DMSO as a 
control for 20 min and then stimulated with LPA (10 µM), Thrombin (2 U/ml) or EGF (3 ng/ml). Cells were 
allowed to migrate into the wound for 12 h. 
 
3.5 The involvement of G protein subunits 
 
While many studies report Gα subunits to be involved in oncogenic signaling (Dhanasekaran 
et al., 1998; Gudermann et al., 2000; Neves et al., 2002), comparably little is known about the 
signaling events induced by Gβγ subunits (Jones et al., 2004). 
The fact that Pertussis toxin abrogates EGFR signal transactivation in many cell lines leads to 
the assumption that Gα subunits, in particular Gαi/o subunits, are involved in the mediation of 
the EGFR signal transactivation (Gschwind et al., 2003; Hart, 2004). The finding that 
constitutively active mutants of Gα subunits encode transforming oncogenes such as gsp, gip2 
and gep (Dhanasekaran et al., 1998; Landis et al., 1989; Lyons et al., 1990; Marinissen and 
Gutkind, 2001; Radhika and Dhanasekaran, 2001; Xu et al., 1993) reinforces the suggestion 
that Gα subunits are key regulators of the EGFR signal transactivation.  
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3.5.1 Overexpression of Gα-subunits 
 
LPA receptors are described to predominanatly couple to Gαi/o subunits, while Thrombin 
receptors often couple to Gα12 and Gα13 subunits (Neves et al., 2002). In contrast, the 
Carbachol receptors are mainly associated with Gαq or Gα11 subunits (Luo et al., 2001). For 
these reasons the following combinations of GPCR ligands and Gα subunits were studied 
(Figure 37). Presumably, the constitutively active mutants of Gα subunits activate the EGFR 
signaling pathway independent from ligand stimulation.  
 
 
 
Fig. 37. Overexpression of different Gα subunits and their activating mutants in COS7 cells. COS7 cells 
were transfected with Gαi2, Gαq, Gα12 and Gα13 subunits as well as the corresponding Gα Q→L mutants. 24 h 
post-transfection, cells were serum-starved for 20 h and subsequently stimulated with 10 µM LPA, 3 ng/ml EGF 
or 100 µM PV, respectively. Equal amounts of cell lysates were immunoprecipitated (IP) with EGFR 108 
antibody and immunoblotted (IB) with PY antibody. Reprobing with EGFR antibody verifies equal loading.  
 
A strongly enhanced EGFR activation was not induced by the expression of any of the  
Gα subunits or their oncogenic mutants. Stimulation with the corresponding stimuli did not 
result in enhanced activation of the EGFR signal (Figure 37). Therefore, the Gα subunits 
affected the EGFR signal transactivation pathway neither in a ligand-dependent nor 
independent fashion. 
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Further analysis of the expression of Gαi2 subunit and its oncongenic variant demonstrated 
that the expression of both subunits lead to increased basal levels of EGFR phosphorylation, 
but merely a slight enhancement after LPA stimulation (Figure 38).  
 
 
 
Fig. 38. Overexpression of Gαi2 subunits in COS7 cells.  COS7 cells were transfected with Mock control, 
Gai2wt or Gαi2Q→L subunit expressing constructs. Cells were starved for 24 h and after preincubation with 
BB94 (5µM, 20 min) or AG1478 (250 nM, 20 min) stimulated with LPA (10µM) or EGF (3ng/ml) for  
3 min. Equal amounts of lysates were immuonprecipitated (IP) with EGFR specific monoclonal antibody and 
immunoblotted (IB) with PY-specific antibody followed by reprobing with anti-EGFR antibody to ensure equal 
loading. Equal amounts of the same lysates were immunoblotted (IB) with P-Erk specific antibody followed by 
reprobing with anti-Erk antibody. 
 
3.5.2 Overexpression of Gβγ subunits  
 
A large variety of Gβ and Gγ subunits are expressed in mammals (Jones et al., 2004). Gβγ 
subunits are suggested to play an important role in the Gi mediated activation of the MAPK 
Erk 1/2 (Crespo et al., 1994; Faure et al., 1994). Additionally, it was discovered that Gβ and 
Gγ are only well expressed in combination, since only the Gβγ dimer is sufficiently stable 
(Luttrell et al., 1997). 
The Gβ1γ2 subunit was tested for its ability to enhance EGFR signal transactivation as well as 
Erk 1/2 activation when overexpressed in various cell lines. Expression of different Gβ1 and 
Gγ2 constructs was examined in COS7 cells as shown in Figure 39.  
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Fig. 39. Gβ1γ2 overexpression in COS7 cells.  COS7 cells were transfected with either Mock control, Gβ1, Gγ2 
or Gβ1 and Gγ2 subunit expressing constructs. Equal amounts of lysates were subjected to SDS-PAGE analysis 
followed by Western blot analysis. Expression of Gβ1 and Gγ2 was detected by Gβ1 and Gγ2 specific antibodies. 
 
The expression of Gβ1 and Gγ2 was well detected (Figure39). These constructs were used for 
further experiments to study the actions of Gβ1γ2 as presented in the following. 
 
3.5.2.1 Influence of Gβγ-subunit overexpression on the EGFR transactivation in 
different cell lines 
 
 
Gβ1 and Gγ2 were coexpressed in Rat1, SCC9, COS7 and HEK239 cells. The ability of the 
Gβ1γ2 subunit to induce activation of the EGFR and the MAPK Erk 1/2 was determined by 
immunoblot analysis as demonstrated in Figures 40 and 41.  
In HEK293 cells, Gβ1 was able to induce Erk 1/2 activation to a comparable extent as 
stimulation with LPA. Gγ2 expression, however, was not be detected (Figure 40).  
 
 
 
Fig. 41. Gβ1γ2 overexpression in HEK293 cells.  HEK293 cells were transfected with either Mock control, Gβ1, 
Gγ2 or Gβ1 and Gγ2 subunit expressing constructs. Cells were starved for 24 h and equal amounts of lyates were 
immunoblotted (IB) with P-Erk specific antibody followed by reprobing with anti-Erk antibody. Expression of 
Gβ1 and Gγ2 was detected by Gβ1 and Gγ2 specific antibodies. 
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Fig. 40. Influence of Gβγ subunits on the EGFR signal transactivation in various cell lines. Rat1 (A), SCC9 
(B) and COS7 (C) cells were transfected with either Mock control, Gβ1, Gγ2 or Gβ1 and Gγ2 subunit expressing 
constructs. Cells were starved for 24h and stimulated with LPA (10µM) or EGF (3ng/ml) for 3 min. Equal 
amounts of lysates were immuonprecipitated (IP) with EGFR specific monoclonal antibody and immunoblotted 
(IB) with PY-specific antibody followed by reprobing with anti-EGFR antibody to ensure equal loading. Equal 
amounts of the same lysates were immunoblotted (IB) with P-Erk specific antibody followed by reprobing with 
anti-Erk antibody. 
 
In Rat1 cells, overexpression of Gβ1γ2 increased EGFR phosphorylation as well as Erk 1/2 
activation (Figure 41). 
Neither in SCC9 nor in COS7 cells, an elevated EGFR or Erk 1/2 activity was demonstrated 
(Figure 41). Therefore, the action of the Gβ1γ2 subunit seemed to be limited to the cellular 
context of Rat1 and HEK293 (Figure 40) and was predominantly mediated by the Gβ1 
subunit. The activation of the EGFR and Erk1/2 is due to the overexpression of Gβ1γ2 and is 
ligand independent. 
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4 Discussion 
 
Crosstalk between members of different receptor families has been recognized to be a  
well-established concept in signal transduction. Signaling networks are essential in the control 
of a variety of cellular processes. GPCRs as well as RTKs belong to the most prominent cell 
surface proteins regulating the cell's response to environmental signals.   
Aberrant signaling of RTKs is known to be crucially involved in the development and 
progression of hyperproliferative diseases such as cancer (Blume-Jensen and Hunter, 2001). 
Constitutive activation of RTKs originates from gene amplification, overexpression, 
activating mutations or autocrine stimulation of the receptors by growth factors (Zwick et al., 
2001). On the other hand, deregulated GPCR signaling by autocrine production of GPCR 
agonists or activating mutations has been frequently associated with different types of human 
cancer (Marinissen and Gutkind, 2001; Moody et al., 2003). Considering the 
pathophysiological significance of both GPCR mediated and direct EGFR signaling, the 
discovery of a pathway connecting these receptors gave rise to extensive studies of said 
pathway.  
This study demonstrated the direct involvement of LPA receptors in the EGFR signal 
transactivation in different cellular contexts. It was demonstrated that the LPA receptors 
activate more that one pathway leading to wound closure. Furthermore, the pathway linking 
GPCR stimulation to the activation of the involved metalloprotease was investigated. 
 
4.1 Reconstituted LPA receptor Edg2 expression in McA-RH7777 cells 
activates a TMPS like mechanism 
 
In order to study the role of LPA receptors in the EGFR transactivation pathway and to assign 
subtype specific action of the LPA receptors Edg2, 4 and 7, a LPA receptor deficient dell line 
was transfected with Edg2, Edg4 or Edg7. Previously, it was shown that ectopic expression of 
Edg2, 4 and 7 in the LPA receptor deficient rat hepatoma cell line MCA-RH7777 leads to 
functional LPA receptor signaling such as intracellular calcium mobilization (An et al., 
1998b). 
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The basal phosphorylation of the EGFR was elevated in the McA-RH7777 cell lines stably 
expressing Edg2 and 4, but LPA stimulation did not lead to significant EGFR activation 
(Figure 13). In Edg2 overexpressing McA-RH7777 cells, LPA stimulation restored Erk 1/2 
activation (Figure 14). The activation of Erk 1/2 was sensitive to treatment by Pertussis toxin 
(PTX), which specifically inhibits Gαi/o subunits, confirming previous studies which 
suggested LPA mediated signaling to be often coupled to Gαi subunits (Takuwa et al., 2002). 
Erk 1/2 activation was independent of src kinase and PI3K function. Interestingly, the 
metalloprotease inhibitor Batimastat and the EGFR inhibitor AG1478 as well as the HB-EGF 
and Pro-Amphiregulin inhibitor Heparin lead to abrogation of the LPA induced Erk 1/2 
activation. Akt 1/2 was also not activated subsequent to LPA stimulation (Figure 15). 
Summarizing the above, the LPA receptors, especially Edg2, activated the MAPK pathway by 
a src family kinase, Akt 1/2 and PI3K independendent, but metalloprotease and EGF-like 
ligand dependent pathway. Although EGFR activation could not be detected, Erk 1/2 
activation was inhibited by the EGFR specific inhibitor AG1478. On the basis of these 
findings, the involvement of a TMPS pathway leading to the activation of Erk 1/2 was 
suggested, although the activation of the EFGR itself could not be demonstrated (Figure 13).  
Two possible explanations for this phenomenon were the following. Either the AG1478 was 
not as specific for the EGFR in rat cells as in human cells hinting at the involvement of a 
closely related receptor tyrosine kinase or a comparably weak activation of the EGFR was 
able induce signaling to Erk 1/2 in McA-RH7777 cells. This hypothesis seemed more 
plausible since also inhibition of the shedding of ligands specifically activating the EGFR 
abrogated Erk 1/2 activation. 
 
4.2 LPA receptor Edg2 function is essential for EGFR signal 
transactivation 
 
Recently, the LPA receptor specific inhibitor Ki16425 was discovered, which is functional 
both in inhibiting short term functions of LPA receptors and long-term actions of LPA 
stimulation such as DNA synthesis and migration (Ohta et al., 2003; Yamada et al., 2004).  
Previous studies reported that LPA and autotaxin stimulated cell motility of neoplastic and 
non-neoplastic cells through Edg2 can be inhibited by Ki16425 (Hama et al., 2004). On the 
contrary, some studies suggested receptor-independent actions for LPA (Hooks et al., 2001). 
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Hence, it was necessary to confirm that the LPA receptors were directly involved in the LPA 
induced transactivation of the EGFR. 
This study clearly demonstrated that in kidney cancer and breast cells Ki16425 abrogated 
LPA induced EGFR signal transactivation and therefore proved, for the first time, the direct 
involvement of LPA receptors, especially Edg2, in the EGFR signal transactivation pathway 
(Figure 24 and Figure 33). 
 
4.3 LPA activates two distinct pathways leading to wound closure 
 
Various studies support the assumption that the EGFR acts as a central integrator of diverse 
GPCR signals (Carpenter, 1999; Gschwind et al., 2001).  
Wound healing is a complex process featuring cell growth and motility as well as chemotaxis. 
Previous reports have shown that LPA enhances in vitro wound closure and invasion in 
ovarian cancer cells (Xu et al., 1995). Additionally, it was observed that LPA stimulates 
closure of wounded monolayers of human endothelial cells (Lee et al., 2000). In vivo data in 
bladder showed that wound healing is mediated by the EGFR and HER2 via processing of 
EGF, TGFα or amphiregulin (Bindels et al., 2002). Metalloproteinase-dependent EGF-like 
ligand shedding has been reported to mediate EGFR transactivation and migration of vascular 
smooth muscle cells (Eguchi et al., 2003). In colon cancer EGFR transactivation by 
Prostaglandin E2 regulates cell migration and invasion (Buchanan et al., 2003). Furthermore, 
it was suggested that LPA is a critical factor regulating motility of pancreatic cancer cells 
(Yamada et al., 2004) and the invasion of ovarian cancer cells (Fishman et al., 2001). Other 
studies indicated the involvement of HB-EGF contributing to migration of prostate cancer 
cells (Madarame et al., 2003) and the modulation of invasion of metastatic breast cancer cells 
by amphiregulin (Kondapaka et al., 1997). The metalloprotease ADAM17/TACE was 
identified as a key element of GPCR-EGFR crosstalk promoting cancer cell motility 
(Gschwind et al., 2003). Recently, the involvement of ADAM 15 in the migration of 
mesangial cells was demonstrated (Martin et al., 2002). The TMPS pathway is believed to 
play a crucial role in the regulation in cell motility and wound closure. 
Here, we present data supporting that GPCR-induced EGFR signal transactivation is one 
pathway leading to wound closure in kidney and breast cancer cells. The LPA receptor itself 
as well as metalloprotease and EGFR function were demonstrated to be involved in the 
migratory behavior of A498, BT549 and MDA-MB 231 cells after LPA stimulation  
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(Figure 25, Figures 34-36). In agreement with these results, Price et al. showed that the breast 
cancer cell line MDA-MB 231 reacts with a potent chemotactic response but not with a 
proliferative response to EGF (Price et al., 1999).  
The LPA receptor inhibitor Ki15425 completely abrogate the chemotactic behavior of kidney 
and breast cells while the inhibition of the TMPS pathway only reduced wound closure 
(Figures 25 and 36). From these results, it was concluded that two different pathways are 
activated upon LPA stimulation, both resulting in chemotaxis. In contrast, Thrombin 
stimulation did not induce wound closure in A498, and BT549 cells even though it is able to 
activate the EGFR (Figure 25, Figure 36).  
Taken together, the results of this study indicated that LPA induced chemotaxis of A498, 
BT549 and MDA-MB-231 cells was regulated by both EGFR independent and dependent 
signaling pathways. Therefore, the Triple-Membrane-Passing signal (TMPS) mechanism of 
EGFR signal transactivation provides only one molecular explanation how GPCR ligands 
regulate chemotaxis and wound closure in breast and kidney cancer cells. 
 
4.4 Combination of LPA and Thrombin leads to enhanced EGFR signal 
transactivation in A498 cells 
 
LPA was previously described to induce EGFR tyrosine phosphorylation in several model 
systems including Rat1 (Daub et al., 1996), HEK293 (Della Rocca et al., 1999), PC-12 (Kim 
et al., 2000), Swiss 3T3 (Gohla et al., 1998), HaCaT and COS7 (Daub et al., 1997). Three 
LPA receptors of the Edg receptor family with differences in G protein-coupling are 
described.  
In A498 cells, LPA stimulated EGFR signal transactivation was not inhibited by PTX  
(Figure 16) suggesting predominantly PTX-insensitive G protein subunits to be involved. On 
the contrary, the Thrombin mediated EGFR signal transactivation was PTX-sensitive and 
therefore was assigned to the Gαi/o family (Figure 19). 
While LPA induced EGFR signal transactivation was mediated by ADAM17 and HB-EGF, 
GPCR-EGFR crosstalk stimulated by Thrombin involved ADAM10 and an EGF-like ligand 
different from HB-EGF, since Heparin was not able to block the TMPS pathway (Figure 18). 
Additionally, this study demonstrated that LPA mediated GPCR-EGFR crosstalk involved a 
src kinase activity upstream of the EGFR (Figure 17). This confirmed previous findings that 
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Src kinase was involved in GPCR-EGFR cross communication (Guerrero et al., 2004) and 
regulated downstream signaling via Erk1/2 and PI3-K/Akt (Das et al., 2004). 
This study proved that both transactivation pathways converge only at the EGFR. In double 
stimulation experiments with LPA and Thrombin, a proportionally increased EGFR signal 
was detected, indicating that the amount of EGFR on the cell surface was not limiting in this 
experiment (Figure 19). To verify the involvement of preclustering of the metalloprotease 
with the GPCR and/or the EGF-like ligand additional lipid raft experiments will be necessary 
in the future. 
 
4.5 Thrombin mediated EGFR signal transactivation is abrogated by 
deregulation of ADAM10 
 
Metalloprotease mediated ectodomain shedding of growth factor precursors in vivo is not yet 
completely understood. Growing evidence suggested the involvement of several members of 
the ADAM family of zinc-dependent proteases in the processing of EGF-like precursors 
(Werb and Yan, 1998). ADAM9 is implicated in the shedding of proHB-EGF by TPA in 
Vero-H cells (Izumi et al., 1998), while LPA-induced proHB-EGF cleavage in the same cell 
system is independent of ADAM9 (Umata et al., 2001). The severe phenotype of mice lacking 
ADAM17 suggests an essential role for this metalloprotease in the processing of proTGFα 
and possibly other EGFR ligands in normal development. Absence of functional ADAM17 
results in impaired basal cleavage of proAR and proHB-EGF in murine fibroblasts (Merlos-
Suarez et al., 2001; Sunnarborg et al., 2002). Recently, Lemjabbar et al. described ADAM17 
to be the responsible sheddase of proAR in the lung cancer cell line NCI-H-292 after 
incubation of the cells with tobacco smoke (Lemjabbar et al., 2003). Recent reports implicate 
ADAM10 (Lemjabbar and Basbaum, 2002; Yan et al., 2002) and ADAM12 (Asakura et al., 
2002) in proHB-EGF-dependent EGFR signal transactivation in MDA-MB 231 cells. The 
detailed regulation of the metalloprotease's specificity remains unclear. Erk has been shown to 
bind and phosphorylate the cytoplasmic tail of ADAM17 at threonine 735 in response to TPA 
stimulation (Diaz-Rodriguez et al., 2002). Experiments with chimeras of TGFα and APP 
propose that the secondary structure of the juxtamembrane region is the important recognition 
element for the sheddase (Arribas et al., 1997).  
This study provided further support for ADAM10 playing a key role in Thrombin induced 
transactivation of the EGFR in A498 cells since the deregulation of ADAM10 by the 
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expression of ADAM10siRNAs lead to abrogation of Thrombin induced EGFR signal 
transactivation (Figures 21 and 22). In order to examine the role of different domains of 
ADAM10 in the activation of the catalytic domain and the shedding of EGF-like ligands, 
A498 cells stably expressing an ADAM10siRNA construct were established. Interestingly, 
long-term silencing of ADAM10 with a siRNA construct targeting the 3'UTR of ADAM10 
also lead to downregulation of ADAM17 expression which made it impossible to ascribe the 
observed effects to the single action of ADAM10 (Figure 23). This finding was in conformity 
with recent findings that long-term siRNA silencing can lead to off-target effects, especially 
downregulation of closely related family members (Scherr and Eder, 2004). 
 
4.6 Inhibitory antibodies against ADAM proteins 
 
Antibodies are potent therapeutics in cancer treatment whereas low molecular weight 
compounds are often less specific and lead to side effects during therapy. The monoclonal 
antibody Trastuzumab targeting HER2 in combination with conventional chemotherapy leads 
to increased survival rates of breast cancer patients (Finn and Slamon, 2003; Ropero et al., 
2004). Acute myeloid leukemia (AML) cell growth can be inhibited by mono-specific and  
bi-specific anti-CD33 x anti-CD64 antibodies (Balaian and Ball, 2004). Recently, a 
monoclonal antibody against the EGF-like ligand cripto was identified to react with various 
cancer, but not normal cells thus providing a novel target for antibody-based immunotherapy 
(Xing et al., 2004). 
In this study, specific antibody sera against ADAM10 and ADAM12 were generated (Figures 
9 and 10). In A498 cells, Thrombin induced EGFR signal transactivation is mediated 
exclusively by ADAM10, while ADAM17 mediated transactivation is induced by LPA (Hart, 
2004; Schafer, 2004; Schafer et al., 2004a).  
Hence, the ADAM10,MP polyclonal serum was tested for its ability to interfere with 
Thrombin mediated EGFR signal transactivation in this cellular context. The serum was able 
to block the GPCR-EGFR cross communication, but this effect could not be assigned to a 
specific binding of ADAM10,MP antibodies as the antibody also interfered with LPA induced 
activation of ADAM17 (Figure 20). Additionally, the preimmune serum showed a similar 
effect. Therefore, the inhibition of the TMPS pathways leading to EGFR signal 
transactivation was unspecifically blocked by serum components. 
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Once a cell line is discovered, in which transactivation of the EGFR stimulated by one agent 
is solely mediated by ADAM12, the ADAM12 serum can be tested for its inhibition 
properties. 
 
4.7 cDNA array analysis of breast cancer cells  
 
cDNA array analysis is a potent method to identify proteins involved in cancer development. 
Normal and cancer samples can be directly compared and abnormal gene expression can be 
detected. Especially for breast cancer it is studied whether gene chip analysis can help to 
predict treatment success (Hampton, 2004). But this method can be used on any type of 
cancer for which important tumor markers are identified. 
LPA was able to induce GPCR-EGFR cross communication in both normal and highly 
invasive breast cancer cell lines examined suggesting that EGFR signal transactivation plays 
an important role in transformed and non-transformed cells (Figure 30). Mammary epithelial 
cells revealed a comparably weak GPCR-induced stimulation of EGFR phosphorylation 
which was attributed to the low EGFR expression level in normal and highly invasive breast 
cancer cell lines as detected in the cDNA array analysis (Figure 32).  
Knyazev has previously shown by cDNA array analysis that the LPA receptor Edg2 is 
overexpressed in a large variety of breast cancer cell lines (Figure 26).  
The data from this cDNA array analysis provided further evidence for the correlation of Edg2 
with the invasive potential of breast cancer cells and the EGFR signal transactivation 
mechanism, because the LPA receptor Edg2 was observed to cluster with proteins which are 
suggested to be involved in the TMPS pathway in breast cancer cells. Edg2 was part of one 
closely related cluster of genes with similar regulation of expression together with the 
metalloproteases ADAM12 and MMP14, the metalloprotease inhibitors TIMP1, 2 and 3 and 
the EGFR ligand HB-EGF (Figure 31).   
The normal breast epithelial cell line MCF10A and the highly invasive cell lines HS578T, 
BT549 and MDA-MB 231 expressed normal to low amounts of the EGFR and HER2, while 
the weakly invasive cell line BT20 exhibited extremely high expression of the EFGR and 
HER2, which explained the high basal activity of the EGFR in these cells.  
The expression pattern correlated with the transactivation behavior: BT20 with a high basal 
EGFR expression and low expression of other components of the TMPS pathway did not 
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induce GPCR-EGFR crosstalk upon LPA stimulation. On the contrary, LPA induced EGFR 
signal transactivation in the other cell lines exhibiting an inverse gene expression pattern. 
The comparison of the gene expression pattern of LPA-stimulated and non-stimulated starved 
breast cancer cells as well as breast cancer cells in normal growth inhibited with the broad 
spectrum metalloprotease inhibitor Batimastat or DMSO as control did not exhibit major 
changes in the gene expression pattern determined in dot blot analysis (data not shown). From 
these results, it was concluded that persistent stimulation with GPCR agonists or repression of 
metalloprotease activity did not alter the gene expression of TMPS pathway related 
components in the investigated time frame of six hours. On the other hand, normal and breast 
cancer cells were clearly separated on the basis of their gene expression pattern. As 
overexpression of components of the TMPS pathway correlates with the invasive potential of 
BT549, HS578T and MDA-MB 231 cells, the GPCR-EGFR crosstalk is presumably involved 
in the invasive behavior of breast cancer cells.  
 
4.8 The involvement of G protein subunits in the TMPS pathway 
 
Many studies suggest Gα subunits to be involved in oncogenic signaling (Dhanasekaran et al., 
1998; Gudermann et al., 2000; Neves et al., 2002). Constitutively active mutants of Gα 
subunits encode transforming oncogenes such as gsp, gip2 and gep (Dhanasekaran et al., 
1998; Landis et al., 1989; Lyons et al., 1990; Marinissen and Gutkind, 2001; Radhika and 
Dhanasekaran, 2001; Xu et al., 1993) suggesting  that Gα subunits are key regulators of the 
EGFR signal transactivation. 
As Pertussis toxin (PTX) abrogates EGFR signal transactivation in many cell lines, it is 
presumed that Gα subunits, especially Gαi/o subunits, are involved in the EGFR signal 
transactivation (Gschwind et al., 2003; Hart, 2004).   
While many studies focus on the Gα subunits, comparably little is known about the signaling 
events induced by Gβγ subunits (Jones et al., 2004). Gβγ subunits are implicated in 
intracellular calcium mobilization, stimulation of PI3K and cyclic AMP production. 
This study investigated the involvement of G protein subunits in the TMPS pathway. 
Overexpression of Gαi2, Gaq, Gα12 and Gα13 subunits as well as their constitutively active 
mutants did not significantly enhance EGFR signal transactivation in COS7 cells. Neither 
ligand-dependent nor independent EGFR signal transactivation was observed for any of the 
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studied Gα subunits (Figure 37 and Figure 38), but as there exist at least 23 Gα subunits 
derived from 17 different genes the number of possibilities are extremely high.  
Gβγ subunits are suggested to play an important role in the Gi mediated activation of the 
MAPK Erk 1/2 (Crespo et al., 1994; Faure et al., 1994). In mammals, 6 Gβ and 12 different 
Gγ subunits are expressed.  
Among these, this study focused on the actions of the Gβ1γ2 subunit in the EGFR signal 
transactivation. Coexpression of Gβ1 and Gγ2 was performed, because it was discovered that 
only the Gβγ dimer is sufficiently stable (Luttrell et al., 1997). Overexpression of the Gβ1γ2 
subunit was able to activate the EGFR and the downstream target Erk 1/2 in a ligand-
independent manner in Rat1 and HEK293 cells (Figures 40 and 41). In SCC9 and COS7 cells 
EGFR activation due to Gβ1γ2 overexpression could not be observed. Therefore, the Gβ1γ2 
subunit was able to mediate EGFR signal transactivation and subsequent Erk 1/2 activation in 
the cellular context of Rat1 and HEK293 cells (Figure 40 and Figure 41).  
 
4.9 Perspectives 
 
Given the importance of EGFR signaling pathways in pathophysiological disease, the factors 
leading to the EGFR signal transactivation, especially the pathway resulting in the activation 
of the metalloprotease have to be elucidated.  
The mechanism leading to the specificity of the ADAM proteins for different EGF-like 
ligands requires further analysis as the same ADAM has varying specificity in different cell 
lines. One possible strategy might be to identify intracellular binding partners of ADAM 
protein using a membrane-based yeast two hybrid screen or pull-down assays.  
It was shown that the β2-adrenergic receptor co-immunoprecipitates with the EGFR receptor 
in stimulated COS7 cells suggesting the formation of a macromolecular complex containing 
other elements of the TMPS pathway (Maudsley et al., 2000).  This preclustering of GPCRs 
with ADAM metalloproteases and EGF-like ligands could be an explanation for the variation 
in specificity of the metalloprotease depending on the stimulus, even though other  
EGF-like ligands are present. Lipid raft experiments as well as FRET (Fluorescence 
Resonance Energy Transfer) or BRET (Bioluminescence Resonance Energy Transfer) 
analysis are further options to verify this hypothesis. In addition, it needs to be clarified if the 
activity of the metalloprotease is regulated by phosphorylation events.  
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A broad spectrum siRNA screening can help to further elucidate the role Gα and Gβγ subunits 
in the EGFR signal transactivation pathway. Additionally, it would be interesting to study the 
involvement of other second messengers such as Ca2+-influx. Further, the role of the recently 
described GPCR oligomerization in the EGFR signal transactivation pathway is of great 
interest (Breitwieser, 2004).  
As stimulation of the LPA receptors does not solely lead to the transactivation of the EGFR 
signal pathway, the importance of both independent pathways in cancer cell development 
have to be further and differentially analyzed. If there is a shift mechanism leading to an 
increase in signal transduction via the EGFR, this mechanism needs to be identified.  
Specific inhibition of single components of the TMPS using low molecular weight inhibitors 
or blocking antibodies can help to gain new insights into the physiological role of this 
pathway and will provide novel therapeutic targets for disease intervention. 
Hardly any in vivo data exists that provides support for the relevance of the EGFR signal 
transactivation pathway. Further, in vivo studies of the EGFR transactivation pathways can 
substantiate the data collected in in vitro studies and prove the relevance of the EGFR signal 
transactivation pathway. EGFR knockout mice have a similar phenotype like TACE knockout 
mice (Hansen et al., 1997). Furthermore, it was demonstrated that TACE regulates TGFα 
ligand availability in vivo (Peschon et al., 1998). HB-EGF knockout mice which mostly die 
early have enlarged, dysfunctional hearts and poorly differentiated lungs (Jackson et al., 
2003). An ADAM 10-deficient mouse displays multiple defects of the central nervous system, 
the somites and the cardiovascular system (Hartmann et al., 2002). Triple null mice lacking 
EGF, amphiregulin, and TGFα are growth retarded and showed intestinal defects (Troyer et 
al., 2001). Mice deficient for three LPA receptors show dysmorphism of the head, 
semilethality due to defective suckling behaviour and generation of a small fraction of pups 
with frontal haematoma (Contos et al., 2002). Further analysis of the EGFR pathway in these 
knock out mice can confirm the existing in vitro data and will give rise to the validation of 
targets of anti-tumor therapy and lead to the development of novel intervention therapies.  
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The most important results from this study were the following: 
 
Reconstitution of LPA receptor expression in McA-RH7777 lead to Erk 1/2 activation 
induced by LPA stimulation depending on a metalloprotease, an EGF-like ligand and RTK 
activity, but was independent of PI3K and src kinase function. Therfore, the activation of a 
TMPS-like pathway was suggested although the direct involvement of the EGFR could not be 
demonstrated. 
 
In A498 cells, the amount of EGFR on the cell surface was not a limiting factor in the EGFR 
transactivation pathway as double stimulation of two independent pathways converging at the 
EGFR was not limited. The involvement of ADAM 10 in Thrombin mediated EGFR signal 
transactivation could be demonstrated by expression of a siRNA construct in A98 cells. 
 
In invasive breast cancer cells Edg2 was upregulated and for the examined breast derived 
cells Edg2 possessed a gene regulation which was similar to the metalloproteases MMP14 
and ADAM12 as well as the metalloprotease inhibitors TIMP1, 2 and 3 and the EGF-like 
ligand HB-EGF.  These genes were observed in one closely related cluster in cDNA array 
analysis. The gene regulation of the EGFR is part of the same cluster as its preferred 
dimerisation partner HER2. However, they were found in a cluster separate from the other 
components of the TMPS pathway. The EGFR expression levels were inversely correlated to 
the invasive potential of these breast cancer cells. 
 
For the first time, the direct involvement of the LPA receptor Edg2 in the EGFR signal 
transactivation pathway was demonstrated both for breast and kidney cancer cells with the 
LPA receptor inhibtor Ki16425. LPA induced wound closure in these cells was not 
exclusively mediated by the EGFR transactivation pathway as the direct inhibition of the LPA 
receptor Edg2 completely abrogated wound closure, while in comparison the broad spectrum 
metalloprotease inhibitor BB94 and the EGFR inhibitor AG1478 merely lead to reduced 
wound closure. 
 
While overexpression of the Gβ1γ2 subunit ligand-independently activated the EGFR signal 
transactivation pathway in a certain cellular context, the Gα subunits and their oncogenic 
mutants did not activate the TMPS pathway neither ligand dependent nor independent. 
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Ab        Antibody 
ADAM       A disintegrin and metalloprotease domain 
Amp       Ampicilline 
Ampr        Ampicilline resistence 
APS        Ammoniumpersulfate 
AR        Amphiregulin 
ATP        Adenosintriphosphate 
bp        Base pairs 
BSA        Bovine serum albumin 
°C        Degree celsius 
cAMP        Cyclic adenosinmonophosphate 
Ca2+        Calcium Ions 
CaM Kinase       Ca2+-calmodulin-dependent kinase 
c-fos        Cellular homologue to v-fos (FBJ murine 
osteosarcoma viral oncogene) 
c-jun   Cellular homologue to v-jun (avian 
sarcoma virus 17 oncogene) 
DAG        Diacylglycerol 
DMEM       Dulbecco's modified eagle medium 
DN        Dominant negative 
DMSO       Dimethylsulfoxide 
DNA        Desoxyribonukleic acid 
dsDNA       Dooble-stranded DNA 
DTT        Dithiothreitol 
ECL        Enhanced chemiluminescence 
EDTA       Ethlendiamintetraacetate 
EGF        Epidermal growth factor 
EGFR        Epidermal growth factor receptor 
EGTA       Ethylene glycol-bis(2-aminoethyl)- 
N,N,N',N'-tetraacetic acid 
ERK        Extracellular signal-regulated kinase 
FAK        Focal adhesion kinase 
FCS        Fetal calf serum 
FGF        Fibroblast growth factor 
FGFR        Fibroblast growth factor receptor 
Fig        Figure 
g        Gramm 
Gab1        Grb2-associated binder-1 
Gab2        Grb2-associated binder-2 
GDP        Guanosindiphosphate 
GPCR        G protein-coupled receptor 
Grb2        Growth factor receptor binding protein 2 
GST        Glutathion-S-transferase 
GTP        Guanosintriphosphate 
h        Hour 
HA        Hemagglutinin 
HB-EGF       Heparin-binding EGF-like growth factor 
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H2Obidest       Twice-destilled, deionised Water 
HEPES       N-(2-Hydroxyethyl)-piperazin-N‘-2- 
Ethansulfonic acid 
HER        Human EGFR-related 
HNSCC       Head and neck squamous cell carcinoma 
Ig        Immunglobulin 
IP        Immunoprecipitation 
IP3        Inositol-1,4,5-trisphosphate 
IPTG        Isopropyl-ß-thiogalactopyranoside 
JNK        c-Jun N-terminal kinase 
kb        Kilobase 
kDa        Kilodalton 
l        Liter 
LPA        Lysophosphatydic acid 
µ        Micro 
m        Milli 
M        Molar 
MAP        Mitogen-activated protein 
MAPK       MAP kinase 
MBP        Myelin basic protein 
MEK       MAPK/ERK Kinase 
min        Minute 
MMP        Matrix metalloprotease 
n        Nano 
OD        Optical density 
p.a.       Per analysis 
PBS        Phosphate-buffered saline 
PCR        Polymerase chain reaction 
PDGF        Platelet-derived growth factor 
PEG        Polyethylenglycole 
PI 3K        Phosphatidylinositol 3-kinase 
PIP2        Phosphatidylinositol-4,5-diphosphate 
PKC        Protein kinase C 
PLC        Phospholipase C 
PMSF        Phenylmethylsulfonyl-fluoride 
PNPP        p-Nitrophenyl-phosphate 
PTX        Pertussis toxin 
PY        Phospho-tyrosine 
Raf        Homologue to v-raf (murine sarcoma viral 
oncogene) 
Ras   Homologue to v-ras (rat sarcoma viral 
oncogene) 
RNA        Ribonucleic acid 
rpm        Rotations per minute 
RT        Room temperature 
RTK        Receptor tyrosine kinase 
SAPK        Stress-activated protein kinase 
S. D.        Standard deviation 
SDS        Natriumdodecylsulfate 
SDS-PAGE       SDS polyacrylamide gel electrophoresis 
sec       Second 
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SH2, 3       domain Src homology 2, 3 domain 
SHP-2       SH2-containing PTP-2 
Sos        Son of sevenless 
src   Homologue to v-src (sarcoma viral 
oncogene) 
TACE        TNFα-converting enzyme 
TCA        Trichloroacetic acid 
TGFα        Transforming growth factor alpha 
TEMED       N, N, N‘, N‘-Tetramethyletylendiamine 
Tet       Tetracycline 
TNFα                  Τumor necrosis factor alpha 
TPA        12-O-Tetradecanoyl-phorbol-13-acetate 
Tris        Tris(hydroxymethyl)aminomethan 
Tween 20       Polyoxyethylensorbitanmonolaureate 
U        Enzymatic activity unit 
o/n        Overnight 
UV        Ultraviolett 
V        Volt 
Vol        Volume 
wt        Wild type 
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